tobramycin has been researched along with Pseudomonas Infections in 718 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 220 (30.64) | 18.7374 |
| 1990's | 76 (10.58) | 18.2507 |
| 2000's | 148 (20.61) | 29.6817 |
| 2010's | 199 (27.72) | 24.3611 |
| 2020's | 75 (10.45) | 2.80 |
| Authors | Studies |
|---|---|
| Furuno, JP; Graffunder, E; Graves, J; Lodise, TP; Lomaestro, B; McGregor, JC; McNutt, LA; Miller, CD | 1 |
| Adams, J; de Oliveira Garcia, D; Doi, Y; Paterson, DL | 1 |
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Borrell, N; Maciá, MD; Moya, B; Oliver, A; Pérez, JL; Plasencia, V | 1 |
| Bajolet, O; Berthelot, P; Bingen, E; Couetdic, G; Favre, R; Grattard, F; Hocquet, D; Husson, MO; Jeannot, K; Mariani-Kurkdjian, P; Marty, N; Plésiat, P; Roussel-Delvallez, M | 1 |
| Bertrand, X; Blanc, K; Hocquet, D; Monnet, DL; Muller, A; Plésiat, P; Talon, D | 1 |
| Chen, T; Khalil, H; Riffon, R; Wang, R; Wang, Z | 1 |
| Attree, I; Elsen, S; Jeannot, K; Köhler, T; Plésiat, P; van Delden, C | 1 |
| Albertí, S; Beceiro, A; Bou, G; Garau, M; Gutiérrez, O; Juan, C; Oliver, A; Pérez, JL | 1 |
| Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
| Gales, AC; Nordmann, P; Picão, RC; Poirel, L | 1 |
| Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L | 1 |
| Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K | 1 |
| Barrow, K; Kwon, DH | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
| Giske, CG; Hermansen, NO; Leegaard, TM; Lia, A; Rajendra, Y; Ranheim, TE; Rydberg, J; Samuelsen, O; Sundsfjord, A; Toleman, MA; Walder, M; Walsh, TR | 1 |
| Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Beceiro, A; Bou, G; Doumith, M; Livermore, DM; Tomás, M; Turton, JF; Warner, M; Woodford, N | 1 |
| Abele-Horn, M; Claus, H; Elias, J; Engelhardt, K; Frosch, M; Joseph, B; Oesterlein, A; Schoen, C; Turnwald, D; Valenza, G | 1 |
| Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
| Chen, CL; Deng, Y; Fyfe, C; Grossman, TH; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY | 1 |
| Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
| Chang, YQ; Chen, WM; Hou, JS; Lin, J; Liu, J; Miao, ZY; Peng, LJ; Sun, PH; Zhang, XY | 1 |
| Hafez, HM; Heil, G; Woernle, H | 1 |
| Abbate, V; Bruce, KD; Cilibrizzi, A; Faure, ME; Hider, RC | 1 |
| Prakash, S; Sindeldecker, D; Stoodley, P | 1 |
| Byun, Y; Ham, SY; Jo, MJ; Kim, HS; Ko, GJ; Lee, JH; Park, HD | 1 |
| Baines, A; Billings, JL; Caverly, LJ; Chmiel, JF; GIbson, RL; Heltshe, SL; Kirby, S; Kong, A; Lascano, J; Mayer-Hamblett, N; Morgan, SJ; Nichols, DP; Nick, JA; Retsch-Bogart, G; Sadeghi, H; Saiman, L; Singh, PK | 1 |
| Bao, X; Bové, M; Coenye, T | 1 |
| Hagiya, H; Inoue, C | 1 |
| Ballmann, M; Blasi, F; Cantin, AM; Chalmers, JD; Elborn, JS; Haworth, CS; Murris-Espin, M; Tiddens, HAWM | 1 |
| Brodlie, M; Shenton, G; Tumelty, H | 1 |
| Buyuksahin, HN; Dogru, D; Emiralioglu, N; Guzelkas, I; Hazirolan, G; Kiper, N; Özçelik, U; Ozsezen, B; Şener, B; Sunman, B; Tural, DA; Yalcin, E | 1 |
| Kopecki, Z; Kral, A; Prestidge, CA; Thomas, N; Thorn, CR; Wignall, A | 1 |
| Häussler, S; Thöming, JG | 1 |
| Fiel, SB; Roesch, EA | 1 |
| De Fabritiis, S; Di Bonaventura, G; Di Nicola, M; Lupetti, V; Piccirilli, A; Pompilio, A; Porreca, A | 1 |
| Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Cai, XJ; Chen, PY; Guan, WJ; Li, RK; Liang, ZA; Liu, XD; Luo, H; Ma, WL; Qu, JM; Song, YL; Tian, DB; Wei, LP; Xu, JF; Xu, XX; Zhang, GJ; Zhang, XJ; Zhang, YJ; Zhao, H; Zhong, NS; Zhu, SY | 1 |
| Clarindo Lopes, L; Hayat, M; Kumar, A; Kuss, S; Li, Y; Lima, D | 1 |
| Fitzgerald, DA; Imani, S; Lai, T; Robinson, PD; Sandaradura, I; Selvadurai, H | 1 |
| Chakraborty, P; Chatterjee, S; Das, A; Das, S; Paul, P; Sarkar, S; Tribedi, P | 1 |
| Friman, VP; Law, JP; Wood, AJ | 1 |
| Berry, N; Byrne, DP; Fernig, DG; Foulkes, DM; Haneef, AS; Kaye, SB; McLean, K; Rustidge, S; Sloniecka, M; Winstanley, C | 1 |
| Coburn, B; DiGiandomenico, A; Eisha, S; Grana-Miraglia, L; Guttman, DS; Hoffman, LR; Howell, PL; McDonald, N; Morris, AJ; Nguyen, D; Park, S; Parsek, MR; Rooney, AM; Wang, P; Waters, VJ; Wozniak, DJ; Yau, YCW | 1 |
| Hernando-Amado, S; Laborda, P; López-Causapé, C; Martínez, JL; Oliver, A; Sanz-García, F | 1 |
| Khan, M; Ma, K; Wan, I; Willcox, MD | 1 |
| Dell, SD; Gatt, D; Ratjen, F; Shaw, M; Solomon, M; Wee, W | 1 |
| Dittrich, AM; Dopfer, C; Fuge, J; Grewendorf, S; Hansen, G; Happle, C; Junge, S; Kontsendorn, J; Rudolf, I; Schütz, K; Sedlacek, L | 1 |
| Baniasadi, S; Hassanzad, M; Kouhestani, F | 1 |
| Dickinson, KM; Mogayzel, PJ | 1 |
| Dumke, M; Hafkemeyer, S; Hammermann, J; Naehrig, S; Naehrlich, L; Schulte-Hubbert, B; Sieber, S | 1 |
| Dhand, R | 1 |
| Abisado-Duque, RG; Cabeen, M; Chandler, JR; Craddock, VD; Holder, AJ; Koirala, P; Mckee, BM; Townsend, KA; Woods, K | 1 |
| Alisoltani, A; Atassi, G; Hauser, AR; Medernach, R; Murphy, KR; Murphy-Belcaster, M; Nozick, S; Ozer, EA; Rhodes, NJ; Scheetz, M | 1 |
| Huang, Y; Liu, H; Lu, W; Peng, J; Qin, G; Wu, D; Xiao, J | 1 |
| Langton Hewer, SC; Rowbotham, NJ; Smith, S; Smyth, AR; Yule, A | 1 |
| Cheng, Z; Fan, X; Liu, X; Mi, Z; Wen, H; Zhang, H; Zhang, Y | 1 |
| Agyeman, AA; Boyce, JD; Bulitta, JB; Cortés-Lara, S; Figuerola, J; Fraile-Ribot, P; Franklyn, ERT; Gomis-Font, MA; Landersdorfer, CB; Lang, Y; Lee, WL; López-Causapé, C; Lucas, DD; Nation, RL; Oliver, A; Rogers, KE; Zhang, Y; Zhou, J | 1 |
| Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Siroosi, M | 1 |
| Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR | 1 |
| Aktas, Z; Boral, O; Issever, H; Oksuz, L; Oncul, O; Sonmez, N | 1 |
| Harris, JK; Mayer-Hamblett, N; Ramsey, BW; Retsch-Bogart, G; Robertson, CE; Sagel, SD; Stevens, MJ; Wagner, BD; Zemanick, ET | 1 |
| Albasri, M; Andrinopoulou, ER; Arets, HGM; Heijerman, HGM; Majoor, CJ; Meerburg, JJ; Tiddens, HAWM; van der Eerden, MM; van der Wiel, EC | 1 |
| Awad, R; Couet, W; Marchand, S; Tewes, F; Torres, BGS | 1 |
| Angyalosi, G; Blasi, F; Chalmers, JD; Elborn, SJ; Goossens, H; Haworth, CS; Hill, AT; Loebinger, MR; Polverino, E; Tiddens, HA; Tunney, M; Zhou, W | 1 |
| Bilton, D; Cipolli, M; Clancy, JP; Eagle, G; Fajac, I; Galeva, I; Gupta, R; Konstan, MW; Liu, K; McGinnis, JP; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A | 1 |
| Carroll, WD; Ditchfield, N; Gilchrist, FJ | 1 |
| Bell, SC; Brockway, B; Lamont, IL; Patrick, WM; Ramsay, KA; Reid, DW; Wardell, SJT; Winstanley, C | 1 |
| Bragonzi, A; Cigana, C; De Fino, I; Melessike, M; Ranucci, S; Rossi, A | 1 |
| Elgaher, WAM; Haupenthal, J; Hirsch, AKH; Lababidi, N; Ofosu Kissi, E; Rades, T; Schneider, M; Schwarz, BC; Sigal, V | 1 |
| Agarwal, A; Nash, EF; Palser, S; Smith, S; Smyth, AR | 1 |
| Gould, FK; Nair, A; Perry, A; Perry, JD; Samuel, J | 1 |
| Bauza, C; Berman, DM; Chojnacki, M; Dudas, RA; Dunman, PM; Fadrowski, JJ; Goldenberg, NA; Morrison, JM | 1 |
| Bergström, CAS; Friberg, LE; Kukavica-Ibrulj, I; Levesque, RC; Sou, T | 1 |
| Gommers, D; Hoek, R; Karami, M; Stokker, J; van der Eerden, M | 1 |
| Armijo, LM; Brandt, YI; Cook, NC; Huber, DL; Kopciuch, M; Monson, TC; Osiński, M; Rivera, AC; Smyth, HDC; Wawrzyniec, SJ; Withers, NJ | 1 |
| Andrinopoulou, ER; Bos, AC; Hamed, K; Mastoridis, P; Meerburg, JJ; Shin, H; Tiddens, HAWM; van Straten, M | 1 |
| Bear, CE; Deber, CM; Laselva, O; Stone, TA | 1 |
| Hernando-Amado, S; Martínez, JL; Sánchez, MB; Sanz-García, F | 1 |
| Cheng, Z; Daboor, SM; Rohde, JR | 1 |
| Paul, C; Schubert, F; Sekundo, W | 1 |
| Mellies, U; Naehrig, S; Sieder, C; Sutharsan, S; Ziegler, J | 1 |
| Anderson, M; Dusane, DH; Li, A; Moore, K; Sindeldecker, D; Stoodley, P; Wozniak, DJ | 1 |
| Angyalosi, G; Blasi, F; Chalmers, JD; Elborn, SJ; Goossens, H; Haworth, CS; Hill, AT; Loebinger, MR; Pathan, R; Polverino, E; Ringshausen, FC; Tiddens, HAWM; Tunney, M | 1 |
| Hu, R; Huang, X; Jin, X; Yuan, K; Zhang, L; Zhu, B | 1 |
| Autry, EB; Beckman, EJ; Gardner, BM; Kuhn, RJ; Saad, A; Schadler, A; Studtmann, AE; Wurth, MA; Young, MR | 1 |
| Ashby, D; Brown, M; Hewer, SCL; Hickey, H; Jones, AP; Kenna, D; Smyth, AR; Thompson, A; Williamson, PR | 1 |
| Rogers, GB | 1 |
| de Souza Carvalho-Wodarz, C; Lababidi, N; Lehr, CM; Montefusco-Pereira, CV; Schneider, M | 1 |
| Fernández-Trujillo, L; Morales, EI; Sangiovanni, S | 1 |
| Aljalamdeh, R; Bolhuis, A; Jones, MD; Price, R | 1 |
| Cetinkaya, E; Chousein, EGU; Çınarka, H; Gul, S; Özgül, MA; Tanriverdi, E; Turan, D; Yildirim, BZ | 1 |
| Aarnivala, H; Niinimäki, R; Peltoniemi, O; Tapiainen, T | 1 |
| Chin, M; Somayaji, R; Thornton, C | 1 |
| Benedetti, A; Kwong, K; Nguyen, D; Waters, V; Yau, Y | 1 |
| Boese, A; de Souza Carvalho-Wodarz, C; Frisch, S; Ho, DK; Horstmann, JC; Huck, B; Lehr, CM; Loretz, B; Murgia, X; Schwarzkopf, K | 1 |
| Caverly, LJ; Chaffee, VD; Dillman, NO; Ochs, MA | 1 |
| Cambridge, L; Millar, BC; Moore, JE; Ollman-Selinger, M | 1 |
| Abdelsamie, AS; Bals, R; Berwanger, A; Blankenfeldt, W; Börger, C; Christmann, R; Empting, M; Hamed, MM; Hartmann, RW; Herr, C; Hirsch, AKH; Ho, DK; Horstmann, JC; Kany, AM; Koch, M; Lehr, CM; Loretz, B; Murgia, X; Röhrig, T; Rox, K; Schmelz, S; Schütz, C; Scrima, A; Siebenbürger, L; Wirth, M; Yahiaoui, S | 1 |
| Burrus, TE; Pettit, RS; Vogt, H | 1 |
| Autry, EB; Bosko, KA; Gardner, BM; Kuhn, RJ; Landmesser, KB; Schadler, A | 1 |
| Kolls, JK; Lu, S | 1 |
| Beaudoin, T; Cw Yau, Y; DiGiandomenico, A; Guttman, DS; Guttman, KM; Hoffman, LR; Jackson, L; Lynne Howell, P; Morris, AJ; Nguyen, D; Parsek, MR; Reichhardt, C; Uwumarenogie, S; Waters, VJ; Wozniak, DJ | 1 |
| Bhatt, J; Nevitt, SJ; Smyth, AR | 1 |
| Cogen, J; Rosenfeld, M | 1 |
| Langton Hewer, SC; Smyth, AR | 3 |
| Hirosako, S; Kamohara, H; Kinoshita, Y; Kohrogi, H; Migiyama, E; Migiyama, Y; Sagishima, K; Tashiro, T; Tokunaga, K | 1 |
| Debonnett, L; Hamed, K | 1 |
| Cao, W; Debonnett, L; Greenwood, J; Hamed, K; Mastoridis, P; Nash, EF; Schwarz, C; Sommerwerck, U; Tamm, M | 1 |
| Anumolu, SS; Koehne-Voss, S; Wang, X; Yu, J | 1 |
| Debonnett, L; Gunda, P; Hamed, K; Panguluri, S | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Ausubel, FM; Gutu, AD; Hebert, W; Joseph-McCarthy, D; Koeva, M; Moskowitz, SM; O'Toole, GA; Wager, JD; Yonker, LM | 1 |
| Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M | 1 |
| Cavallaro, G; Craparo, EF; Cusimano, MG; Giammona, G; Porsio, B; Schillaci, D | 1 |
| Bahamondez-Canas, TF; Leal, J; Smyth, HDC; Tewes, F; Zhang, H | 1 |
| Baig, NF; Bohn, PW; Dunham, SJB; Ellis, JF; Madukoma, CS; Morales-Soto, N; Shrout, JD; Sweedler, JV | 1 |
| Bae, H; Chi, YT; Choi, GW; Choi, HJ; Jang, MC; Jo, AR; Ku, YG; Lee, DJ; Nam, J; Sung, HY | 1 |
| Alon, N; Angyalosi, G; Asherova, I; Maykut, R; McKinney, ML; Moeller, A; Ratjen, F | 1 |
| Bahamondez-Canas, TF; Ferrati, S; Moraga-Espinoza, DF; Smyth, HDC | 1 |
| Bartezaghi, M; Blasi, F; Carnovale, V; Cimino, G; Lucidi, V; Messore, B; Muscianisi, E; Porpiglia, PA; Salvatore, D | 1 |
| Armstrong, R; Felix, LM; Grundy, S; Harrison, H; Lynes, D; Milan, SJ; Spencer, S | 1 |
| Accurso, F; Albers, G; Black, P; Brown, P; Buckingham, R; Cairns, A; Davis, SD; Graff, GR; Kerby, GS; Kloster, M; Mayer-Hamblett, N; Orenstein, D; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M | 1 |
| Garg, N; Whiteley, M | 1 |
| Ali, AA; Ghadam, P; Gharavi, S; Tavafi, H | 1 |
| Adams, C; Ahmadi, S; Bear, CE; Beaudoin, T; Deber, CM; Glibowicka, M; Grasemann, H; Stone, TA; Waters, V; Yau, Y | 1 |
| Galega, R; Greene, JN; Lee, GC; Quilitz, R; Shurko, J; So, W | 1 |
| Bähre, H; Felgner, S; Häussler, S; Müsken, M; Pawar, V; Schwebs, T; Weiss, S | 1 |
| Barnes, LA; Demirel, N; Gaillard, PR; Menk, JS; Regelmann, WE; Wey, AR | 1 |
| Charbek, E; Rowbotham, NJ; Smith, S | 1 |
| Maiden, MM; Waters, CM; Zachos, MP | 1 |
| Claude, F; Hafen, GM; Rochat, I | 1 |
| Cogen, JD; Goss, CH; Nichols, DP; Nick, JA; Nick, SE; Russell, R; Saavedra, MT; Somayaji, R; Taylor-Cousar, JL | 1 |
| Davis, S; Doiron, A; Gil, J; Goodwine, J; Higa, A; Sauer, K; Solis, M; Valdes, J | 1 |
| Klingel, M; Ratjen, F; Stanojevic, S; Tullis, E; Waters, V | 1 |
| Avery, LM; DeRonde, KJ; Kuti, JL; Motos, A; Mullane, EM; Nicolau, DP | 1 |
| Baravalle-Einaudi, M; Dubus, JC; Dupont, C; Le Pennec, D; Vecellio, L | 1 |
| Ascenzioni, F; Cavallaro, G; De Rocco, D; Di Domenico, EG; Giammona, G; Porsio, B; Santucci, R; Sardo, C | 1 |
| Baker, P; Dellos-Nolan, S; Hill, PJ; Howell, PL; Lacdao, I; Parsek, MR; Passos da Silva, D; Pestrak, MJ; Raju, D; Silver, H; Wozniak, DJ | 1 |
| Coenye, T; Crabbé, A; Daled, S; Deforce, D; Dhaenens, M; Ostyn, L; Rigauts, C; Risseeuw, M; Staelens, S; Van Acker, H; Van Calenbergh, S | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Alkadri, J; Mostofian, F; Radhakrishnan, D; Tang, K; Thampi, N | 1 |
| Ammeter, D; Arthur, G; Idowu, T; Schweizer, F; Zhanel, GG | 1 |
| Grimwood, K; Harun, SN; Hennig, S; Holford, NHG; Wainwright, CE | 1 |
| Alghanem, SS; Thomson, AH; Touw, DJ | 1 |
| Caceres, S; Caverly, L; Fratelli, C; Kim, SH; Malcolm, K; Moskowitz, S; Nichols, DP; Nick, JA; Poch, KR; Saavedra, M; Solomon, G; Taylor-Cousar, J | 1 |
| Cantón, R; Girón, RM; Lamas, A; Máiz, L; Mensa, J; Olveira, C; Pastor, D; Quintana, E | 1 |
| Brackman, G; Coenye, T | 1 |
| Kemper, AL; Young, DC; Zobell, JT | 1 |
| Amin, RS; Carle, AC; Chini, BA; Fenchel, MC; Huang, B; McPhail, GL; Seid, M; VanDyke, RD | 1 |
| Elkin, EP; Emerson, J; Gibson, RL; Khan, U; Konstan, MW; Mayer-Hamblett, N; Morgan, W; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Thompson, V; Treggiari, MM; Wagener, J | 1 |
| Beegle, S; Butterfield, JM; Farkas, J; Lodise, TP; Pai, MP; Rosen, J | 1 |
| Diamond, P; Elborn, JS; McCaughey, G; McKevitt, M; Tunney, MM | 1 |
| Elborn, JS; Gilpin, DF; Hoffman, LR; McCaughey, G; McKevitt, M; Schneiders, T; Tunney, MM | 1 |
| Angyalosi, G; Geller, DE; He, E; Higgins, M; Nasr, SZ; Piggott, S | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Mathew, JL; Ratjen, F; Stanojevic, S; Taylor, L; Waters, V | 1 |
| Alipour, M; Lui, EM; Omri, A; Suntres, ZE | 1 |
| Pierart, F | 1 |
| McKeage, K | 1 |
| Al-Aloul, M; Nazareth, D; Walshaw, M | 1 |
| Cantrell, A; Carroll, C; Harnan, S; Mildred, M; Tappenden, P; Uttley, L | 1 |
| Brownlee, K; Cantrell, A; Harnan, S; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
| Brownlee, K; Harnan, S; Mildred, M; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
| Confreda, K; LaPlante, K; Shurko, J; Tarquinio, K | 1 |
| Clark, P; Knight, H; Nolan, K | 1 |
| Djapgne, L; Nguyen, AT; Oglesby-Sherrouse, AG; Vasil, AI; Vasil, ML | 1 |
| Antipkin, YG; Blanco-Aparicio, M; Bolbas, K; Chiron, R; Chuchalin, A; Cicirello, HG; Geidel, C; Kucerova, T; Mazurek, H; Santoro, D; Varoli, G; Zibellini, M | 1 |
| Babcock, CI; Cook, KE; Fabiilli, ML; Fowlkes, JB; Orizondo, RA; Pavlovsky, L; Younger, JG | 1 |
| Chmiel, JF; Forssén, AV; Kim, SH; Moskowitz, SM; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL | 1 |
| Cheney, J; Hennig, S; McKay, K; O'Brien, K; Stacey, S; Vidmar, S; Wainwright, CE | 1 |
| Baek, JY; Cho, SY; Chung, DR; Kang, CI; Kim, J; Kim, SH; Ko, KS; Peck, KR; Song, JH | 1 |
| Steinkamp, G | 1 |
| McColley, SA | 1 |
| Barry, PJ; Jones, AM | 1 |
| Eustace, JA; Fleming, C; Harrison, MJ; Hickey, C; McCarthy, M; Murphy, DM; Plant, BJ; Shortt, C | 1 |
| Gąszczyk, G; Mazurek, H; Sands, D; Sapiejka, E | 1 |
| Fiel, SB | 2 |
| Deane, J; Denys, GA; Goering, RV; Locke, JB; Sahm, DF; Scharn, CR; Shaw, KJ; Zuill, DE | 1 |
| Bratton, DL; Burns, JL; Caceres, SM; Malcolm, KC; Moskowitz, SM; Nichols, DP; Nick, JA; Saavedra, MT; Taylor-Cousar, JL | 1 |
| Bode-Böger, SM; Kirchner, R; Knobloch, JK; Krajewski, J; Martens-Lobenhoffer, J; Mittelstädt, H; Mulrooney, T; Russlies, M; Tröger, U | 1 |
| Tappenden, P; Uttley, L | 1 |
| Buyck, JM; Tulkens, PM; Van Bambeke, F | 1 |
| Abdelghany, SM; Deacon, J; Donnelly, RF; Elborn, JS; Gilmore, BF; Jones, DS; Kissenpfennig, A; Megaw, J; Quinn, DJ; Schmid, D; Scott, CJ; Taggart, CC | 1 |
| Dasenbrook, EC; Konstan, MW; VanDevanter, DR | 1 |
| Aaron, SD; Bell, SC; Conrad, D; Dudley, MN; Fischer, R; Flume, PA; Geller, DE; Kerem, E; Loutit, JS; Morgan, EE; Smyth, AR; Stuart Elborn, J; VanDevanter, DR | 1 |
| Elborn, JS; Shteinberg, M | 1 |
| Cooper, R; Howe, R; Jenkins, R; Wootton, M | 1 |
| Parkins, MD; Somayaji, R | 1 |
| Antoniu, S | 1 |
| Daines, CL; Farquharson, R; Higuchi, K; Schechter, MS; Trueman, D | 1 |
| Bielecki, P; Gocht, B; Häussler, S; Kasnitz, N; Komor, U; Moter, A; Pawar, V; Pils, MC; Rohde, M; Weiss, S | 1 |
| Farinde, A | 1 |
| Beaudoin, T; Clark, S; Coburn, B; Guttman, DS; Hwang, DM; Smith, L; Vidya, P; Waters, V; Yau, YC | 1 |
| Hebert, WP; Mastoridis, P; O'Toole, GA; Orazi, G; Price, KE; Ruoff, KL | 1 |
| Kotsimbos, T; Langan, KM; Peleg, AY | 1 |
| Alonso, T; Ancochea, J; Cisneros, C; Garcia, J; Garcia-Castillo, E; Giron, RM; Gomez-Punter, RM; Marcos, C; Valenzuela, C; Vazquez-Espinosa, E; Zamora, E | 1 |
| Heuer, HE; Krippner, F; Merkel, N; Posselt, HG; Rietschel, E; Sieder, C; Staab, D; van Koningsbruggen-Rietschel, S; Ziegler, J | 1 |
| Dorrestein, PC; Frydenlund Michelsen, C; Hossein Khademi, SM; Ingmer, H; Jelsbak, L; Krogh Johansen, H | 1 |
| Bachiller, D; Esquisabel, A; Fleischer, A; Moreno-Sastre, M; Palomino, E; Pastor, M; Pedraz, JL; Sans, E; Viñas, M | 1 |
| Angyalosi, G; Debonnett, LM; Flume, PA; Galeva, I; Konstan, MW; Maykut, RJ; Wan, R | 1 |
| Baziard, G; El Hage, S; Furiga, A; Lajoie, B; Roques, C | 1 |
| Bassenden, AV; Berghuis, AM; Rodionov, D; Shi, K | 1 |
| Cabot, G; Cantón, R; López-Causapé, C; Macià, MD; Moyà, B; Oliver, A; Pérez, JL; Rojo-Molinero, E; Rubio, R | 1 |
| Cohen, F; Elborn, JS; Flume, PA; Loutit, J; VanDevanter, DR | 1 |
| Panfilov, DN; Suvorov, VV; Vysotskaya, LV; Yur'ev, NV | 1 |
| Bergen, PJ; Hirsch, EB; Kirkpatrick, CM; Landersdorfer, CB; McIntosh, MP; Peleg, AY; Walsh, CC | 1 |
| Bresnik, M; Clancy, JP; Derchak, PA; Flume, PA; Lewis, SA; Ramsey, BW; Retsch-Bogart, GZ; Tullis, DE | 1 |
| Kappe, E; Kempf, H; Schade, B; Schmitt, F; Wibbelt, G; Widmer, D; Ziemssen, E | 1 |
| Angyalosi, G; Cao, W; Debonnett, L; Sommerwerck, U; Viegas, A; Virella-Lowell, I | 1 |
| Douce, GR; Evans, TJ; McCaughey, LC; Ritchie, ND; Walker, D | 1 |
| Kim, SY; Lee, HS; Park, MH; Roh, EY | 1 |
| Akeda, Y; Hagiya, H; Takimoto, K; Tanaka, T; Tomono, K; Yamamoto, N; Yoshida, H | 1 |
| Graepler-Mainka, U; Hellwig, D; Herrmann, G; Heuer, HE; Heyder, S; Kinder, B; Köster, H; Kröger, K; Melichar, VO; Mellies, U; Paul, K; Poplawska, K; Riethmüller, J; Smaczny, C | 1 |
| Bowling, FL; Dobson, CB; Lovering, AM; Price, BL | 1 |
| Christiansen, G; Dueholm, MS; Geifman-Shochat, S; Kjelleberg, S; Meyer, RL; Nielsen, PH; Otzen, DE; Seviour, T; Stenvang, M; Søndergaard, MT; Vad, BS; Zeng, G | 1 |
| Elborn, JS; van der Ent, CK | 1 |
| Cavallaro, G; Craparo, EF; Cusimano, MG; Giammona, G; Porsio, B; Schillaci, D; Spigolon, D | 1 |
| Lazova, S; Miteva, D; Perenovska, P; Petrova, G; Strateva, T | 1 |
| Bratcher, PE; Caceres, SM; Chmiel, JF; Happoldt, CL; Malcolm, KC; Nichols, DP; Nick, JA; Saavedra, MT; Saiman, L; Taylor-Cousar, JL | 1 |
| Calhoun, JH; Diamond, SM; Dusane, DH; Farrar, NR; Granger, JF; Howlin, RP; Knecht, CS; Nocera, TM; Peters, CW; Plaut, RD; Stoodley, P; Swearingen, MC | 1 |
| Iglewski, BH; Wagner, VE | 1 |
| George, AM; Iredell, J; Middleton, PG; Treerat, P; Widmer, F | 1 |
| Rubin, BK | 1 |
| Heijerman, HG; Kingma, H; Rijntjes, E; Scheenstra, RJ; Tavy, DL | 1 |
| Chan, J; Charron, M; Coates, AL; Green, M; Keller, M; Leung, K; Louca, E; Ratjen, F; Ribeiro, N; Tservistas, M | 1 |
| Boer, AH; Brun, PP; Frijlink, HW; Heijerman, HG; Roldaan, AC; Touw, DJ; Westerman, EM | 1 |
| Chavanet, P; Croisier, D; Martha, B; Piroth, L | 1 |
| Martins, A; Pandya, VB; Sharma, S | 1 |
| Moreau-Marquis, S; O'Toole, GA; Stanton, BA | 1 |
| Etchebere, EC; Grotta, MB; Ribeiro, AF; Ribeiro, JD; Ribeiro, MA; Romanato, J | 1 |
| Ahern, JW; Corriveau, M; Lahiri, T; Van Meter, DJ | 1 |
| Naranjo-Tackman, R; Stangogiannis-Druya, C; Stangogiannis-Druya, E; Vanzzini, V; Villar-Kurí, J | 1 |
| Cleveland, KO; Gelfand, MS; Mazumder, SA | 1 |
| Bertram, C; Elborn, JS; Hodson, M | 1 |
| Boni, V; Braccini, G; Braggion, C; Campana, S; Festini, F; Galici, V; Neri, AS; Taccetti, G; Trevisan, F; Zavataro, L | 1 |
| Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E | 1 |
| Emerson, J; Gibson, RL; Kronmal, RA; Mayer-Hamblett, N; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Treggiari, MM; Williams, J | 1 |
| Amelina, E; Bianco, F; Chuchalin, A | 1 |
| Delaisi, B; Dominique, S; Hubert, D; Kho, P; Kovarik, JM; Leroy, S; Mely, L; Murris-Espin, M; Nove-Josserand, R | 1 |
| Angermeyer, A; Bauerle, E; Hinz, A; Juhaszova, K; Kaneko, Y; Lee, S; Manoil, C; Singh, PK | 1 |
| Angyalosi, G; Brockhaus, F; Ratjen, F | 1 |
| Ballmann, M; Claass, A; Doering, G; Franke, P; Junge, S; Riethmueller, J; Schroeter, TW; Stern, M; von Butler, R | 1 |
| Ballmann, M; Broemme, S; Claass, A; Doering, G; Franke, P; Hebestreit, A; Jeschke, R; Junge, S; Koetz, K; Kuemmerer, K; Riethmueller, J; Schroeter, TW; Staab, D; Stern, M | 1 |
| Gregori-Roig, P; Pantoja-Martínez, J; Valls-López, S; Yagüe-Muñoz, A | 1 |
| Bjarnsholt, T; Calum, H; Christensen, LD; Christophersen, L; Ciofu, O; Givskov, M; Hougen, HP; Høiby, N; Jensen, PØ; Molin, S; Moser, C; van Gennip, M | 1 |
| Angyalosi, G; Kho, P; Munck, A; Ratjen, F | 1 |
| Elborn, JS; Goldsmith, CE; Maeda, Y; Moore, JE; Rendall, JC | 1 |
| Blázquez, J; Castañeda-García, A; Couce, A; Gómez, C; Maciá, MD; Oliver, A; Rodríguez-Rojas, A | 1 |
| Christodoulou, E; Eckhardt, BP; Nasr, SZ; Sakmar, E; Streetman, DS; Strouse, PJ | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM | 1 |
| Accurso, FJ; Harris, JK; Sagel, SD; Wagener, JS; Wagner, BD; Zemanick, ET | 1 |
| Clarkin, O; Cooney, J; Thornton, R; Towler, M; Wren, A | 1 |
| Smyth, AR | 1 |
| Cacciarelli, TV; Muder, RR; Shields, RK; Singh, N; Sun, HY | 1 |
| Griese, M; Hector, A; Kappler, M | 1 |
| Brown, R; Sacco, P; Woodward, TC; Zhang, J | 1 |
| Baquero, F; Cantón, R; del Campo, R; García-Castillo, M; Morosini, MI; Turrientes, MC; Zamora, J | 1 |
| Abele-Horn, M; Frosch, M; Hebestreit, H; Horn, S; Oesterlein, A; Radike, K; Schoen, C; Valenza, G | 1 |
| Chermenskiĭ, AG; Gembitskaia, TE | 1 |
| Adeboyeku, D; Hodson, ME; Jones, AL | 1 |
| Döring, G; Herrmann, G; Høiby, N; Molin, S; Riethmüller, J; Song, Z; Ulrich, M; Wang, H; Wu, H; Yang, L | 1 |
| Angyalosi, G; Brockhaus, F; Geller, DE; Konstan, MW; Minić, P; Zhang, J | 1 |
| Balzli, CL; Caballero, AR; McCormick, CC; O'Callaghan, RJ; Tang, A | 1 |
| Angyalosi, G; Brockhaus, F; Chiron, R; Flume, PA; Geller, DE; He, E; Higgins, M; Kappler, M; Konstan, MW; Zhang, J | 1 |
| Briesacher, BA; Fouayzi, H; Quittell, LM; Quittner, AL; Sacco, P; Saiman, L | 1 |
| Berlana, D; Jódar, R; Llop, JM; Manresa, F | 1 |
| Davis, GA; Feola, DJ; Hayes, D; Kuhn, RJ; Murphy, BS | 1 |
| Mitov, I; Petrova, G; Strateva, T | 1 |
| Cho, E; Davidson, AG; Lillquist, YP | 1 |
| Geller, DE; Heuerding, S; Weers, J | 1 |
| Chan, J; Charron, M; Coates, AL; Denk, O; Edwardes, M; Green, M; Keller, M; Leung, K; Martin, S; Ribeiro, N | 1 |
| Bosso, JA; Church, EC; Mauldin, PD | 1 |
| Knox, A; Smyth, A | 1 |
| Li, Y; Liu, MT; Sheng, MY; Zhang, Y | 1 |
| Cottingham, L; Langley, A | 1 |
| Latremouille-Viau, D; Sawicki, GS; Shi, L; Signorovitch, JE; von Wartburg, M; Wu, EQ; Zhang, J | 1 |
| Burns, JL; Gibson, RL; Khan, U; Kronmal, RA; Mayer-Hamblett, N; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Treggiari, MM | 1 |
| Cohen, MB; Saiman, L | 1 |
| Burns, JL; Chatfield, BA; Froh, DK; Gibson, RL; Hiatt, P; Khan, U; Kronmal, R; Kulich, M; Mayer-Hamblett, N; Orenstein, D; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Spencer, T; Treggiari, MM; Williams, J | 1 |
| Chang, CL; Kuhn, RJ; Stephenson, JJ; Wertz, DA; Zhang, J | 1 |
| Elborn, JS; Parkins, MD | 1 |
| Bhavsar, T; Cantor, J; Liu, M; Liu, X | 1 |
| Narten, M; Rosin, N; Schobert, M; Tielen, P | 1 |
| Bahniuk, N; Bonomo, RA; Brown, D; Bulitta, JB; Defiglio, H; Drawz, SM; Drusano, GL; Fikes, S; Kulawy, R; Louie, A; Vanscoy, B | 1 |
| Beck, JF; Mainz, JG; Michl, R; Pfister, W | 1 |
| Geller, DE; Kissner, DG; McColley, SA; McKevitt, M; Montgomery, AB; Moorehead, L; Rolfe, MW; Rosen, JM; Trapnell, BC | 1 |
| Elborn, JS; McCaughey, G; McKevitt, M; Tunney, MM | 1 |
| Ballmann, M; Geller, DE; Smyth, A | 1 |
| Alhede, M; Bjarnsholt, T; Christensen, LD; Givskov, M; Hougen, HP; Høiby, N; Jakobsen, TH; van Gennip, M | 1 |
| Alhede, M; Bjarnsholt, T; Christensen, LD; Eberl, L; Friedrich, K; Givskov, M; Høiby, N; Jakobsen, TH; Jensen, PØ; Larsen, TO; Moser, C; Nielsen, KF; Phipps, RK; Rasmussen, TB; Shanmugham, MS; Skindersoe, ME; Tanner, D; Uthe, F; van Gennip, M | 1 |
| Bhatt, J; Smyth, AR | 1 |
| Arnold, HM; Kollef, MH; Sawyer, AM | 1 |
| Bianchini, E; Buzzetti, R; Campana, S; Cariani, L; Costantini, D; Taccetti, G; Trevisan, F; Zavataro, L | 1 |
| Bruscia, EM; Dietrich, LE; Gao, Y; Kazmierczak, BI; Motterlini, R; Murray, TS; Okegbe, C | 1 |
| Balp, MM; Kulich, K; Regnault, A; Viala-Danten, M | 1 |
| Angyalosi, G; Balp, MM; Capkun-Niggli, G; Doering, G; Higashi, K; Jansen, JP; Littlewood, KJ; Tiddens, HA | 1 |
| Boulanger, L; De Boeck, K; Proesmans, M; Verhaegen, J; Vermeulen, F | 1 |
| Griffin, EF; Moreau-Marquis, S; O'Toole, GA; Schwartzman, JD; Stanton, BA; Yu, Q | 1 |
| Moore, ME; Mueller, EW | 1 |
| Assael, BM; Bilton, D; Bresnik, M; Chiron, R; Fayon, M; Fischer, R; Knoop, C; LaRosa, M; Lewis, SA; McElvaney, N; Montgomery, AB; Oermann, CM; Pressler, T | 1 |
| Bell, SC; Goss, CH | 1 |
| Griswold, KE; Lamppa, JW | 1 |
| Döring, G; Goldman, MH; Haliburn, C; Schuster, A | 1 |
| Alhariri, M; Omri, A | 1 |
| Acerbi, D; Annoni, O; Cicirello, H; Govoni, M; Poli, G; Ružička, J; Santoro, D | 1 |
| Jahnke, N; Remmington, T; Ryan, G | 1 |
| Arıkan Ayyıldız, Z; Bahar, IH; Fırıncı, F; Karaman, M | 1 |
| Govan, J | 1 |
| Alothman, GA; Alsaadi, MM; Coates, AL; Corey, M; Dupuis, A; Ho, BL; Ho, SL | 1 |
| Bitzan, MM; Hoffmann, IM; Iskandar, SS; Nagaraj, SK; Rubin, BK; Schechter, MS | 1 |
| Gallagher, CG; Govan, JR; Hodson, ME | 1 |
| Accurso, F; Burns, JL; Dovey, M; Emerson, J; Gibson, RL; Hamblett, N; Hiatt, P; Konstan, MW; McNamara, S; Moss, R; Ramsey, B; Retsch-Bogart, G; Rosenfeld, M; Wagener, J; Waltz, D; Wilmott, R; Yunker, A; Zeitlin, PL | 1 |
| Borel, B; Charara, O; Foucaud, P; Nathanson, S; Petitprez, P; Pin, I | 1 |
| Rothman, KJ; Wentworth, CE | 1 |
| Higham, PA; Scott, CP | 1 |
| Cheng, LL; Cheung, EY; Lam, DS; Leung, AT; Wong, AK; Young, AL | 1 |
| Burns, JL; Fiel, SB; Mayer-Hamblett, N; Ramsey, B; Smith, AL | 1 |
| Adriensen, B; Husson, MO; Loiez, C; Massoni-Cristante, S | 1 |
| Sloan, B; Watson, A | 1 |
| Pitt, TL; Sparrow, M; Stefanidou, M; Warner, M | 1 |
| Cook, FV; Gavin, PJ; Peterson, LR; Suseno, MT; Thomson, RB | 1 |
| Fleiszig, SM; Lee, EJ; Mendoza, MN; Truong, TN | 1 |
| Cheer, SM; Noble, S; Waugh, J | 1 |
| Brennan, AL; Geddes, DM | 1 |
| Tiddens, H | 1 |
| Ariano, RE; Harding, GK; Iacovides, H; Zelenitsky, SA | 1 |
| Fish, DN; Jung, R; MacLaren, R; Obritsch, MD | 1 |
| Bugnon, D; Caillon, J; Gras-Le Guen, C; Jacqueline, C; Kergueris, MF; Navas, D; Potel, G | 1 |
| Brey, RH; Edson, RS; McCarthy, JT; McDonald, TJ; Terrell, CL; Thibert, JM | 1 |
| Smith, AL | 1 |
| Bowman, CM | 1 |
| Gallagher, CG; Hodson, ME | 1 |
| Govan, JR | 1 |
| Drummond, M; Iles, R; Legh-Smith, J; Prevost, A; Vowler, S | 1 |
| Drobnic, ME; Ferrer, A; Montoro, JB; Orriols, R; Suñé, P | 1 |
| Bertran, S; Gómez, E; Jiménez de Anta, MT; Julià, A; Ruiz, J; Sauca, G; Vila, J; Vila, X | 1 |
| Abe, M; Araki, M; Horimi, T; Nasu, Y; Ono, N; Takahashi, I | 1 |
| Devi, NA; Doss, VA; Parvathi, S; Raju, BA | 1 |
| Coulthard, K; Lind, A; Madsen, V; Rasmussen, M | 1 |
| Bjarnsholt, T; Burmølle, M; Calum, H; Givskov, M; Haagensen, JAJ; Hentzer, M; Hougen, HP; Høiby, N; Jensen, PØ; Madsen, KG; Molin, S; Moser, C | 1 |
| Higashiyama, Y; Hirakata, Y; Kohno, S; Miyazaki, Y; Morinaga, Y; Nakamura, S; Ohno, H; Tashiro, T; Yanagihara, K | 1 |
| Elborn, S; Moriarty, F; Tunney, M | 1 |
| Andrés, MT; Fierro, JF; Pérez, F; Viejo-Diaz, M | 1 |
| Lobue, PA | 1 |
| Scheinberg, P; Shore, E | 1 |
| Horrevorts, AM; Jacobs, N; Mouton, JW; Tiddens, H | 1 |
| Adrean, SD; Cochrane, R; Mannis, MJ; Reilly, CD | 1 |
| Ahya, VN; Bloom, RD; Blumberg, EA; Christie, JD; Doyle, AM; Kotloff, RM; Lipson, DA; Mendez, JD; Nelson, L; Pochettino, A | 1 |
| Campbell, P; Marshall, BC; Mayer-Hamblett, N; Saiman, L | 1 |
| Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
| Baquero, F; Cantón, R; García-Castillo, M; Loza, E; Morosini, MI; Pérez-Vázquez, M | 1 |
| Blumer, JL; Konstan, MW; Melnick, D; Saiman, L | 1 |
| Elborn, JS; Field, TR; Tunney, MM; White, A | 1 |
| Bourget, C; Lafleur, L; Lagacé, J; Lapointe, JR; Mainville, S; Montplaisir, S | 1 |
| Borriello, G; Ehrlich, GD; Richards, L; Stewart, PS | 1 |
| Balke, B; Häussler, S; Hogardt, M; Hoy, L; Schmoldt, S; Weissbrodt, H | 1 |
| Smyth, AR; Wood, DM | 1 |
| Borrell, N; Gómez, C; Maciá, MD; Oliver, A; Pérez, JL; Segura, M | 1 |
| Sharma, N; Singhvi, A; Sinha, R; Tandon, R | 1 |
| Chavanet, P; Croisier, D; Durand, D; Hocquet, D; Martha, B; Piroth, L; Plesiat, P; Portier, H | 1 |
| Bossuyt, X; Godding, V; Leal, T; Lebecque, P; Reychler, G; Zylberberg, K | 1 |
| Campana, S; Ciuti, R; De Martino, M; Festini, F; Repetto, T; Taccetti, G | 1 |
| Hyman-Taylor, P; Knox, A; Lewis, S; Mulheran, M; Smyth, A; Stableforth, D; Tan, KH | 1 |
| Adeboyeku, D; Hodson, ME; Scott, S | 1 |
| Bell, J; Conway, SP; Coulthard, KP; Peckham, DG; Smith, CA; Turnidge, J | 1 |
| Burkhardt, O; Derendorf, H; Kumar, V; Lehmann, C; Madabushi, R; Welte, T | 1 |
| Cannella, CA; Wilkinson, ST | 1 |
| Ratjen, F | 1 |
| Bilton, D; Gotfried, M; Henig, N; Morrissey, B | 1 |
| Arias, M; Calabia, ER; de Francisco, AL; Gomez-Alamillo, C; Izquierdo, MJ; Ortiz, F; Ruiz, JC | 1 |
| Conrad, C; Geller, DE; Konstan, MW; Noonberg, SB; Smith, J | 1 |
| Baracco, G; Cohn, SM; Crookes, B; Habib, F; Hallal, A; Manning, RJ; Namias, N; Schulman, CI | 1 |
| Antunes, MB; Chiu, AG; Cohen, NA; Palmer, JN | 1 |
| Korzeniewska, A; Stelmach, I; Stelmach, W | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 1 |
| Accurso, FJ; Acton, J; Burns, JL; Chatfield, BA; Emerson, J; Gibson, RL; Hiatt, P; Konstan, MW; Mayer-Hamblett, N; McNamara, S; Moss, R; Ramsey, BW; Retsch-Bogart, G; Waltz, DA; Williams, J; Zeitlin, P | 1 |
| Acerbi, D; Corrado, ME; Eichler, HG; Eichler, I; Pennini, R; Poli, G; Soliani Raschini, A | 1 |
| Antypkin, YG; Aryayev, NL; Lenoir, G; Miano, A; Monici Preti, PA; Moretti, P; Varoli, G; Zanda, M | 1 |
| Bartnicka, MT; Chuchalin, A; Csiszér, E; Gyurkovics, K; Kapranov, N; Mazurek, H; Monici Preti, PA; Sands, D; Varoli, G | 1 |
| Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE | 1 |
| Boyle, MP; Diener-West, M; Goss, CH; Lechtzin, N; Marshall, BC; Merlo, CA | 1 |
| Hasan, MA; Lange, CF | 1 |
| Elborn, JS; McElnay, JC; Moriarty, TF; Tunney, MM | 1 |
| Elborn, JS; Moriarty, TF; Tunney, MM | 1 |
| Akova, M; Altun, B; Gürkan Aydin, N; Hasçelik, G; Metan, G; Zarakolu, P | 1 |
| Moye, RA; Nisly, SA; Ray, SM | 1 |
| Faia, LJ; Griepentrog, GJ; Schornack, MM | 1 |
| Anderson, GG; Bomberger, JM; Moreau-Marquis, S; O'Toole, GA; Stanton, BA; Swiatecka-Urban, A; Ye, S | 1 |
| Bracco, D; Dubois, MJ; Eggimann, P; Landry, C | 1 |
| Balzli, C; Caballero, A; McCormick, C; O'Callaghan, R; Song, J; Tang, A | 1 |
| Anderson, GJ; Lamont, IL; Reid, DW | 1 |
| Armero Ibáñez, R; Lluch Oltra, A; Sifre Julio, C; Solaz Roldán, C | 1 |
| Ambinder, R; Israel, E; Levitt, R; Lietman, PS; Lipsky, JJ; Longstreth, J; Mellits, ED; Petty, BG; Rocco, L; Smith, CR | 1 |
| Higham, M | 1 |
| Falkiner, FR; Jacoby, GA; Keane, CT; McCann, SR | 1 |
| Johnson, CE; Pennington, JE; Platt, R | 1 |
| Ott, PM; Vogt, M | 1 |
| Fitzpatrick, SB; Rosenstein, BJ | 1 |
| Bricaire, F; Bure, A; Humbert, G; Vachon, F; Vilde, JL | 1 |
| Ashley, MA; Kim, C; Montgomerie, JZ; Schick, DG | 1 |
| Angehrn, P | 1 |
| Alfredson, H; Ericsson, A; Malmborg, AS; Strandvik, B | 1 |
| Christensen, HO; Høiby, N; Koch, C; Møller, AF; Møller, S; Permin, H | 1 |
| Fleming, PC; Gold, R; Isles, A; Jin, E; Levison, H | 1 |
| Connor, PJ; David, TJ; Phillips, BM | 1 |
| Cox, CE | 1 |
| Koup, JR; Levy, J; Ramsey, B; Smith, AL; Williams-Warren, J | 1 |
| Bodey, GP; Bolivar, R; Elting, L; Fainstein, V; Keating, MJ; McCredie, KB | 1 |
| Chusid, MJ; Davis, SD; Sarff, LD | 1 |
| Batten, JC; Hodson, ME; Wingfield, HJ | 1 |
| Chanturiia, TsK; Kharitonova, AM; Moroz, AF | 1 |
| Heilesen, AM; Høiby, N; Koch, C; Permin, H | 1 |
| Lerner, AM; Reyes, MP; Rintelmann, WF; Tablan, OC | 1 |
| Chervenick, P; Diven, WF; Muder, RR; Yu, VL; Zuravleff, JJ | 1 |
| Drake, TA; Hackbarth, CJ; Rusnak, MG; Sande, MA | 1 |
| Pennington, JE; Schiff, JB; Small, GJ | 1 |
| Petri, WH; Schaberg, SJ | 1 |
| Gelender, H; Rettich, C | 1 |
| Eriksen, KR; Feddersen, C; Flensborg, EW; Høiby, N; Møller, NE; Norn, S; Rosendal, K; Schiøtz, PO; Skov, PS | 1 |
| DeHertogh, D; Peacock, JE; Tashjian, L; Yu, VL; Zuravleff, JJ | 1 |
| Pennington, JE; Schiff, JB | 1 |
| Hoogkamp-Korstanje, JA; van der Laag, J | 1 |
| Kinberg, P | 1 |
| Flensborg, EW; Høiby, N; Szaff, M | 1 |
| Alfredsson, H; Malmborg, AS; Strandvik, B | 1 |
| DeBoer, G; Duncan, I; Feld, R; Moran, L; Pinfold, P; Rachlis, A; Tuffnell, PG | 1 |
| Lisitsa, LI; Rudzit, EA; Zinchenko, TA; Zukakova, IB | 1 |
| Jimenez, EM; Lindquist, LB; Montgomerie, JZ; Morrow, JW; Sapico, FL | 1 |
| Leong-Sit, L; Okumoto, M; Smolin, G | 1 |
| Davis, SD; Hyndiuk, RA; Sarff, LD | 8 |
| Schmülling, RM; Ullmann, U | 1 |
| Duncan, IB; Duncan, NH; Rennie, RP | 1 |
| Sanders, CC; Sanders, WE | 1 |
| Blackwood, LL; Pennington, JE | 1 |
| Boat, TF; Cheng, PW; Powell, SH; Reed, MD; Stern, RC; Vermeulen, MW | 1 |
| Asche, V; Holloway, BW; Morgan, AF; Sinclair, MI | 1 |
| Kluge, RM | 1 |
| Chow, MS; Nightingale, CH; Quintiliani, R | 1 |
| Norden, CW; Shaffer, MA | 1 |
| Johnson, CE; Pennington, JE | 1 |
| Baran, D; Klastersky, J; Levy, J | 1 |
| Hall, G; Haynes, BW; Kline, BJ; Mayhall, CG; Polk, RE; Smith, J; Swensson, E | 1 |
| Bloxham, DD; Cash, HA; DiScenna, AO; Groden, DL; Grossniklaus, DA; Jacobs, MR; Klinger, JD; Luthe, MA; Powell, SH; Stern, RC; Thompson, WL | 1 |
| Calicchio, G; Centrone, G; Ragno, G | 1 |
| Bagley, DH; Herlihy, E; McGuire, EJ | 1 |
| Cagle, G; Laibson, P; Michaud, R; Okumoto, M; Rosenthal, A; Smolin, G | 1 |
| Fan, L; Kelly, HB; Menendez, R; Murphy, S | 1 |
| Hatley, LH; Kessler, JM; McCartney, CF | 1 |
| Cortelezzi, A; Radaelli, F; Savarè, M | 1 |
| Ansorg, R; Behrens-Baumann, W; Paul, HH | 1 |
| Arnulf, JJ; Diesnis, P; Dor, V; Gioanni, T; Jourdan, J; Kreitmann, P; Mermet, B; Schmitt, R | 1 |
| Bigi, E; Luppi, A; Sangiorgi, A | 1 |
| Hiraga, Y; Kikuchi, K; Nakahashi, M | 1 |
| Roy, I; Thadepalli, H | 1 |
| Russo, ME | 1 |
| Binder, WJ; Kamer, FM | 1 |
| Anderson, CM; George, RH; Healing, DE; Martin, AJ; Smalley, CA | 1 |
| Davidson, TM; Light, M; Mitchell, M; Murphy, C; Smith, C | 1 |
| Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ | 1 |
| Bastone, EB; Cousins, VC; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW | 1 |
| Ciofu, O; Giwercman, B; Høiby, N; Pedersen, SS | 1 |
| Chow, AW; Gallimore, B; Laverdière, M; Poonia, K; Restieri, C | 1 |
| Bakker, W; Heijerman, HG; Hermans, J; Touw, DJ; Vinks, AA | 1 |
| Beaulac, C; Bouhajib, M; Lagacé, J; Montplaisir, S; Omri, A; Sharkawi, M | 1 |
| Eftimimiadou, A; Kaliengidou, M; Kartali, S; Panagoutsos, S; Papazoglou, D; Pasadakis, P; Thodis, E; Vargemezis, V | 1 |
| Baxter, CR; Horton, JW; Price, CI | 2 |
| Berant, M; Lichtig, C; Makhoul, IR; Merzbach, D | 1 |
| Cohen, KL; Lauffenburger, MD | 1 |
| Beagley, MJ; Kelman, GJ; Roland, GC | 1 |
| Douwes-Idema, AE; Hoogeterp, JJ; Lim, T; Mattie, H; Moffie, BG | 1 |
| Astley, SJ; Dorkin, HL; Eisenberg, JD; Gibson, RL; Harwood, IR; Kravitz, RM; McBurnie, MA; Ramsey, BW; Schidlow, DV; Wilmott, RW | 1 |
| Costerton, JW; Jass, J; Lappin-Scott, HM | 1 |
| Hernandez, JE; Kerns, FT; Teague, AC | 1 |
| Irby, NL; Sweeney, CR | 1 |
| Jenni-Galović, V; Nikolaizik, WH; Schöni, MH | 1 |
| Barclay, ML; Begg, EJ; Chambers, ST; Grimwood, K; Pattemore, PK; Thornley, PE | 1 |
| Beaulac, C; Clément-Major, S; Hawari, J; Lagacé, J | 1 |
| Anstine, D; Lakhdir, F; Neiberger, R; Slayton, W; Sleasman, J | 1 |
| de Blok, K; Prins, JM; Speelman, P; van Ketel, RJ; Weverling, GJ | 1 |
| Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE | 1 |
| Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B | 1 |
| Ategbo, S; Druon, D; Elian, JC; Farriaux, JP; Gottrand, F; Launay, V; Loeuille, GA; Turck, D; Vic, P | 1 |
| Aebischer, CC; Mordasini, C; Schoch, OD | 1 |
| Ben-David, J; Brodsky, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I | 1 |
| Battles, A; Liu, QF; Liu, W; Louie, A; Miller, DA; Miller, MH; Sucke, AC | 1 |
| Donzis, PB | 1 |
| Hostacká, A; Majtán, V | 1 |
| Bauernfeind, A; Döring, G; Przyklenk, B; Ratjen, F; Steinkamp, G; von der Hardt, H; Wiesemann, HG | 1 |
| Ben-David, J; Brodzki, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I | 1 |
| Das, GK; Kumar, A; Panda, A; Vanathi, M | 1 |
| Arrouet-Lagande, C; Ategbo, S; Deschildre, A; Druon, D; Husson, MO; Launay, V; Loeuille, GA; Sardet, A; Turck, D; Vic, P | 1 |
| Girkin, CA; Miller, NR; Perry, JD; Reich, SG | 1 |
| Chaudhry, NA; Davis, J; Miller, D; Rosenfeld, PJ; Tabandeh, H | 1 |
| Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P | 1 |
| Borowitz, D; Bowman, CM; Marshall, BC; Marshall, S; Montgomery, AB; Otto, KL; Pepe, MS; Quan, JM; Ramsey, BW; Smith, AL; Vasiljev-K, M; Williams-Warren, J | 1 |
| Albers, GM; Burns, JL; Garber, RL; Montgomery, AB; Otto, KL; Quan, JM; Ramsey, BW; Shawar, RM; Smith, AL; Van Dalfsen, JM | 1 |
| Bowler, SD; McCormack, JG; Wolter, JM | 1 |
| Po, AL; Scott, EM; Tariq, VN; Wu, YL | 2 |
| Hazinski, TA | 1 |
| Akbar, A; English, MW; Nyamugunduru, G; Rees, JH; Spencer, DA; Weller, PH | 1 |
| Campbell, PW; Saiman, L | 1 |
| Beaulac, C; Lagacé, J; Sachetelli, S | 1 |
| Alper, CM; Bagger-Sjobak, D; Dohar, JE; Gulhan, M; Hebda, PA; Ozunlu, A; Swarts, JD | 1 |
| Birnbaum, H; Greenberg, P; LeLorier, J; Perreault, S; Sheehy, O | 1 |
| Beringer, PM; Jelliffe, RW; Shapiro, BJ; Vinks, AA | 1 |
| González Lama, Z; Lupiola Gómez, P; Martín Barrasa, JL; Tejedor Junco, MT | 1 |
| Bärmeier, H; Bartel, K; Böwing, B; Habash, T; Heininger, U; Lugauer, S; Schoerner, C; Unsal, M | 1 |
| Jones, J; Prober, CG; Walson, PD | 1 |
| Alothman, GA; Gysin, C; Papsin, BC | 1 |
| Baghurst, PA; Colebatch, KA; Coulthard, KP; Hansman, D; Holmes, M; Jarvinen, A; Kennedy, D; Linke, RJ; Martin, A; Martin, AJ; Master, V; Onishko, CR; Parsons, DW; Roberts, GW; Roberts, ME | 1 |
| Golovanova, V; Hakanen, M; Kolho, E; Lyytikäinen, O; Ruutu, P; Sivonen, A; Tiittanen, L; Vuopio-Varkila, J | 1 |
| He, G; Li, H; Xu, H | 1 |
| Moss, RB | 2 |
| Couch, LA | 1 |
| LiPuma, JJ | 1 |
| Bingen, E; Bonacorsi, S; Brahimi, N; Gérardin, M; Lebourgeois, M; Mariani-Kurkdjian, P; Munck, A; Navarro, J | 1 |
| Döring, G; Nikolaizik, WH; Ratjen, F | 1 |
| Hyman-Tylor, P; Knox, A; Mulheran, M; Smyth, A; Tan, KH | 1 |
| Hubert, D; Sermet-Gaudelus, I; Turck, D | 1 |
| Bogle, S; Caldwell, NA; Conway, SP; Etherington, C; Setchfield, N; Whitehead, A | 1 |
| Campana, S; Farina, S; Procopio, E; Repetto, T; Taccetti, G | 1 |
| Assael, BM; Candusso, M; Faraguna, D; Marchetti, F | 1 |
| Griese, M; Müller, I; Reinhardt, D | 1 |
| Flume, PA; Kuhn, RJ | 1 |
| Buu, A; Quittner, AL | 1 |
| Hurwitz, ME; Nasr, SZ; Spigarelli, MG | 1 |
| Halter, J; Lewis, RP; Meyer, RD; White, M | 1 |
| Pennington, JE | 2 |
| Brown, WJ; El-Khatib, MR; Lerner, AM; Reyes, MP; Smith, F | 1 |
| Prociv, P | 1 |
| Robertson, IF | 1 |
| Friis, B | 1 |
| Davis, SD | 2 |
| Horwitz, MJ; Templeton, TP | 1 |
| Neu, HC; Parry, MF | 2 |
| Balcke, P; Graninger, W; Kopsa, H; Pils, P; Schimatzek, A; Schmidt, P; Zazgornik, J | 1 |
| Schimpff, SC | 1 |
| Hopefl, AW | 1 |
| Bodey, GP; Feld, R; Rodriguez, V; Valdivieso, M | 1 |
| Fox, L; Gurwith, MJ; Lank, B; Marrie, TJ; Ronald, AR; Stiver, HG | 1 |
| Basker, MJ; Comber, KR; Osborne, CD; Sutherland, R | 1 |
| Keys, TF; Washington, JA | 1 |
| Washington, JA; Yu, PK | 1 |
| Clancy, MT; Dalton, M; Falkiner, FR; Jacoby, GA; Keane, CT | 1 |
| Bryan, CS; Longaker, DW; Saunders, DE; Smith, CW; Sutton, JP | 1 |
| Alpren, TV; Davis, SD; Hyndiuk, RA; Sarff, LD | 1 |
| Bender, SW; Knothe, H; Paporisz, U; Posselt, HG; Ristow, W; Röser, D; Wönne, R | 2 |
| Bak-Pedersen, K; Friis, B; Jensen, K; Larsen, PK; Thomsen, J | 1 |
| Friis, B; Thomsen, J | 2 |
| Benn, RA | 1 |
| Motoyama, M; Nishizuka, K; Ogawa, T; Oishi, M | 2 |
| Brown, WJ; Lerner, AM; Reyes, MP | 1 |
| Dawson, DA | 1 |
| Goering, RV; Sanders, CC; Sanders, WE | 1 |
| Abbate, GF; Altucci, P; Gattoni, A; Leonessa, V | 1 |
| Archer, G; Blair, DC; Bruce, B; Fekety, FR; Silva, J | 1 |
| Hartmann, I; Metz, H; Ohgke, H | 1 |
| Belfort, R; Kim, HB; Okumoto, M; Smolin, G | 1 |
| Cherubin, CE; Evans, HE; Hochstein, L; Khan, AJ | 1 |
| Medvedeva, MM; Rastunova, GA; Shcherbakova, EG; Sobolev, VR | 1 |
| Fiala, M; Mandal, AK; Oparah, SS; Thadepalli, H | 1 |
| Cstáry, KN; Iván, E | 1 |
| Crozier, DN; Khan, SR | 1 |
| Dessaut, B; Dulong de Rosnay, HL; Grimont, PA; Lesgouarres, MT | 1 |
| Bailey, RR; Peddie, B | 1 |
| Burch, KH; Cox, F; Del Busto, R; Fisher, E; Haas, EJ; Madhavan, T; Quinn, EL | 1 |
| Gerding, DN; Hall, WH; Schierl, EA | 1 |
| Gill, SS; Kramer, NE; Patel, R; Towne, WD | 1 |
| Johnston, PG; Speller, DC | 1 |
| Dzierzanowska, D | 1 |
| Raine, PA; Young, DG | 1 |
| McCrae, WM | 1 |
| Baron, D; Courtieu, A; Drugeon, H; Nicolas, F | 1 |
| Fabre, S; Hilmer, R; Jennis, F; Vincent, PC | 1 |
| Ishiyama, S; Iwai, S; Iwamoto, H; Murata, I; Nakayama, I; Ohashi, M | 1 |
| Hanson, EJ; McCrae, WM; Raeburn, JA | 1 |
| Kunz, LJ; Moellering, RC; Wennersten, C | 1 |
| Häusler, R; Lehmann, W; Waldvogel, FA | 1 |
| Lüthy, R | 1 |
| Kaiser, AB; McGee, ZA | 1 |
| Kampmann, JP | 1 |
| Clinch, TE; Engel, LS; Hill, JM; Hobden, JA; Kaufmann, HE; O'Callaghan, RJ | 1 |
| Assil, KK; Brown, SI; Douglas, H; Frucht-Perry, J; Schanzlin, DJ; Weinreb, RN; Ziegler, E | 1 |
| Gonzalez, VH; Gritz, DC; Kwitko, S; McDonnell, PJ; Trousdale, MD | 1 |
| Nicolau, D; Nightingale, CH; Quintiliani, R | 1 |
| Igari, H; Ishiyama, N; Kanno, H; Kawashima, T; Kikuchi, N; Kohno, N; Kuriyama, T; Miyazaki, RM; Muraki, N; Onozaki, I | 1 |
| Gandolfi, SA; Massari, A; Orsoni, JG | 1 |
| Assil, KK; Fouraker, BD; Schanzlin, DJ; Zarnegar, SR | 1 |
| Boudreau, RJ; Budd, JR; duCret, RP; Kuni, CC; Regelmann, WE | 1 |
| Fichtenbaum, CJ; Smith, MJ | 1 |
| Gritz, DC; Gwon, A; Hubbard, BB; Lee, TY; McDonnell, PJ; Tang-Liu, D | 1 |
| Hrdy, DB; Kailath, EJ; King, JH | 1 |
| Kowalski, RP; Stuart, JC; Turgeon, PT | 1 |
| Assil, KK; Frucht-Perry, J; Schanzlin, DJ; Schneiderman, T; Weinreb, RN; Ziegler, E | 1 |
| Bowes, G; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW; Spicer, WJ; Tong, N | 1 |
| Jurado, R; Kindelan, JM; López-Villarejo, P; No-Louis, E | 1 |
| Forman, K; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ | 1 |
| Cooper, JA; Cowan, RG; Lepow, M; Mayer, D; Winnie, GB; Witson, J | 1 |
| Bromley, HR; Brundage, DM; Brundage, RC; Uber, WE; White, RL | 1 |
| Acosta, M; González, M; Iñigo, MA; Rojas, E; Sánchez, A | 1 |
| Bakhache, P; Chivet, C; Douchain, F; Houdas, S; Lebas, L; Pautard, JC | 1 |
| Semsarian, C | 1 |
| Habal, MB; Turkeltaub, SH | 1 |
| Cunha, BA; George, LJ | 1 |
| Matteson, EL; McCune, WJ | 1 |
| Gritz, DC; Kwitko, S; Lee, TY; McDonnell, PJ | 1 |
| Gordon, JJ; Kauffman, CA | 1 |
| Albus, A; Döring, G; Gappa, M; Potel, J; Steinkamp, G; Tümmler, B; von der Hardt, H | 1 |
| Grimwood, K; Rabin, HR; To, M; Woods, DE | 1 |
| Gadebusch, HH; Gilfillan, EC; Pelak, BA; Valiant, ME | 1 |
| Filippos'iants, ST; Shevniuk, LA; Vinogradova, IV | 1 |
| Friedlaender, MH; Hodges, EJ; Lee, A; Okumoto, M | 1 |
| Ehrlich, M; Mondino, BJ; Weissman, BA | 1 |
| Minukhin, VV; Tsyganenko, AIa | 3 |
| Corey, M; Gold, R; Levison, H; MacLusky, IB | 1 |
| De Boeck, K; Eggermont, E; Smet, M | 1 |
| Anwar, H; Costerton, JW; Dasgupta, M; Lam, K | 1 |
| Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ; Rootman, DS; Thompson, HW | 1 |
| Gore, EJ; Hack, B; Hedges, DL; Ramsey, BW; Redding, GJ; Smith, AL; Weber, A; Williams-Warren, J | 1 |
| Malottke, R; Steinkamp, G; Tümmler, B; von der Hardt, H | 1 |
| McCall, CY; Spruill, WJ; Wade, WE | 1 |
| Moore, CM | 1 |
| Alfonso, E; Baerveldt, G; Becker, MI; Heseltine, PN; Kenyon, KR; Ormerod, LD; Smith, RE | 1 |
| Bransby-Zachary, MA; Hawkey, PM; Millar, MR; Myles Gibson, R; Tompkins, DS | 1 |
| Ehrich, JH; Gröne, HJ; Lütge, M; Schulz-Baldes, JG; Steinkamp, G; Wurster, U | 1 |
| Costerton, JW; Ladd, TI; Nickel, JC; Schmiel, D | 1 |
| Gratz, JC; Maserati, R; Scheld, WM; Strunk, RW | 1 |
| Gilbert, ML; Osato, MS; Wilhelmus, KR | 2 |
| Farrand, SK; Mucha, DK | 1 |
| Høiby, N; Koch, C; Pedersen, SS; Rosendal, K | 1 |
| Kapusnik, JE; Sande, MA | 2 |
| Minukhin, VV; Tsyganenko, VIa | 1 |
| Morgan, JR; Paull, A | 1 |
| Rubio, TT; Shapiro, C | 1 |
| Chambers, HF; Hackbarth, CJ; Sande, MA; Shibl, AM; Stella, F | 1 |
| Andriole, VT; Johnson, M; Miniter, P | 1 |
| Bentzon, MW; Høiby, N; Jensen, T; Koch, C; Pedersen, SS; Pressler, T; Rosdahl, VT | 1 |
| Pennington, JE; Small, GJ | 1 |
| Bailey, EJ; Chandrasekar, PH; Crane, LR | 1 |
| Gordin, FM; Rusnak, MG; Sande, MA | 1 |
| Hilf, M; Korvick, J; Yu, VL | 1 |
| Bosso, JA; Matsen, JM; Saxon, BA | 1 |
| Bryan, LE; Chamberland, S; Godfrey, AJ; Ogunariwo, J; Rabin, HR; Schryvers, AB | 1 |
| Gonzalez, JR; Hill, JM; Hobden, JA; Jantzen, JA; O'Callaghan, RJ; Rootman, DS | 1 |
| Hoogeterp, JJ; Mattie, H; Terporten, P | 2 |
| Black, PG; Bosso, JA | 1 |
| Black, PG; Herbst, JJ; Jennison, K; Kane, RE; Wood, C | 1 |
| Damas, P; Osterrieth, PM; Rousseaux, D | 1 |
| Bennett, WM; Brummett, RE; Gilbert, DN; Houghton, DC; Kohlhepp, SJ; Kohnen, PW; Norton, DR; Porter, GA; Wood, CA | 1 |
| Dick, JD; Gottsch, JD; O'Brien, TP; Sawusch, MR | 1 |
| Bayer, AS; Parr, TR | 1 |
| Hill, JM; Hobden, JA; O'Callaghan, RJ; Rootman, DS | 1 |
| Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ; Rootman, DS | 1 |
| Kim, YD; Levine, MR; Witt, W | 1 |
| Norden, CW; Shinners, E | 1 |
| Gappa, M; Steinkamp, G; Tümmler, B; von der Hardt, H | 1 |
| Hulstaert, PF; Kerver, AJ; Mevissen-Verhage, EA; Rommes, JH; Verhoef, J; Vos, A; Wittebol, P | 1 |
| Fraser-Smith, EB; Matthews, TR | 1 |
| Jacobs, RF | 1 |
| Cabinian, AE; Kaatz, GW | 1 |
| Carswell, F; Cook, DA; Speller, DC; Ward, C | 1 |
| Aronoff, SC; Cohn, RC; Jacobs, M | 1 |
| Carpenter, T; Chambers, HF; Hackbarth, CJ; Kapusnik, JE; Sande, MA | 1 |
| Black, P; Blumer, J; Craft, JC; Halsey, NA; McCarty, JM; Tilden, SJ; Waring, W | 1 |
| Flensborg, EW; Høiby, N; Jensen, T; Koch, C; Pedersen, SS | 1 |
| Breit, R; Nade, S | 1 |
| Donnenfeld, ED; Laibson, PR | 1 |
| Jimenez-Lucho, VE; Medeiros, AA; Pohlod, D; Saravolatz, LD | 1 |
| Bartlett, FF; Campbell, DR | 1 |
| Friis-Møller, A; Høiby, N; Koch, C; Pedersen, M; Pressler, T; Stenvang Pedersen, S | 1 |
| Rubio, TT | 1 |
| Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE | 1 |
| Horner, GW; Stempel, DA | 1 |
| Jensen, T; Osterhammel, D; Osterhammel, P; Pedersen, SS | 1 |
| de Witte, J; Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hop, WC; Horrevorts, AM; Kerrebijn, KF; Michel, MF | 1 |
| Canawati, HN; Gilmore, DS; Graham, IE; Ibraham, MZ; Montgomerie, JZ; Morrow, JW | 1 |
| Brasfield, DM; Jewett, CV; Ledbetter, J; Lyrene, RK; Tiller, RE | 1 |
| Conway, SP; Littlewood, JM; Miller, MG; Ramsden, C | 1 |
| Byrd, RG; Cone, LA; Stoltzman, DS; Woodard, DR | 1 |
| Borges, LF; Chapman, PH | 1 |
| Grassi, C | 1 |
| Chait, G; McNeely, DJ; Salit, IE | 1 |
| Kany, RJ; Zar, FA | 1 |
| Antsiferova, NG; Moroz, AF; Radkevich, SA; Vetkova, LG | 1 |
| Boike, SC; Erickson, SR; Levine, DP; Rybak, MJ | 1 |
| Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hermans, J; Horrevorts, AM; Kerrebijn, KF; Michel, MF | 1 |
| Corbin, RP; Fraser, GL; Grimes, GR; Valenti, AJ | 1 |
58 review(s) available for tobramycin and Pseudomonas Infections
| Article | Year |
|---|---|
Bronchiectasis and inhaled tobramycin: A literature review.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
The use of tobramycin for Pseudomonas aeruginosa: a review.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Lung; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin | 2022 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Infant; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Forced Expiratory Volume; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Tobramycin | 2019 |
Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.
Topics: Administration, Inhalation; Bronchiectasis; Chronic Disease; Disease Progression; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin; Treatment Outcome | 2021 |
Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Body Mass Index; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Injections, Intravenous; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Vital Capacity; Young Adult | 2017 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory System; Tobramycin | 2017 |
Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Medication Adherence; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin | 2017 |
Dual antibiotics for bronchiectasis.
Topics: Adult; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Gentamicins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2018 |
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Forced Expiratory Volume; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Ticarcillin; Tobramycin | 2018 |
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Colistin; Cystic Fibrosis; Humans; Lung Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2013 |
Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Child, Preschool; Clinical Trials as Topic; Costs and Cost Analysis; Cystic Fibrosis; Drug Interactions; Female; Forced Expiratory Volume; Humans; Male; Nebulizers and Vaporizers; Powders; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Young Adult | 2013 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Child; Cystic Fibrosis; Disease Progression; Gentamicins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2013 |
[TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Clinical Trials as Topic; Cystic Fibrosis; Dry Powder Inhalers; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2013 |
Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2013 |
Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Topics: Administration, Inhalation; Child; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Disease Progression; Humans; Outcome Assessment, Health Care; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Tobramycin; United Kingdom | 2013 |
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Disease Progression; Dry Powder Inhalers; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Lung; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Time Factors; Tobramycin; Treatment Outcome | 2013 |
[Dry powder inhalers in cystic fibrosis].
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Diuretics, Osmotic; Drug Compounding; Dry Powder Inhalers; Humans; Mannitol; Powders; Pseudomonas Infections; Tobramycin | 2014 |
Aerosolized antibiotics in cystic fibrosis: an update.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2014 |
Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Dry Powder Inhalers; Humans; Medication Adherence; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2014 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2014 |
Use of inhaled tobramycin in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Dry Powder Inhalers; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2015 |
Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Drug Delivery Systems; Dry Powder Inhalers; Humans; Medication Adherence; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Technology, Pharmaceutical; Tobramycin | 2015 |
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Fungal; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2015 |
Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Cystic Fibrosis; Dry Powder Inhalers; Humans; Lung; Opportunistic Infections; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2016 |
Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Aortic Valve; Drug Therapy, Combination; Echocardiography, Transesophageal; Endocarditis; Endocarditis, Bacterial; Foramen Ovale, Patent; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Intermittent Urethral Catheterization; Magnetic Resonance Imaging; Male; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Ultrasonography, Doppler | 2016 |
P. aeruginosa Biofilms in CF Infection.
Topics: Animals; Azithromycin; Biofilms; Cystic Fibrosis; DNA, Bacterial; Gene Expression Regulation, Bacterial; Humans; Immunity, Mucosal; Immunocompromised Host; Lung; Opportunistic Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Tobramycin | 2008 |
Aerosolized antibiotics for non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bronchiectasis; Clinical Trials as Topic; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Tobramycin | 2008 |
Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Nutritional Status; Patient Compliance; Pseudomonas Infections; Quality of Life; Respiratory Function Tests; Tobramycin | 2009 |
Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2009 |
[Use of inhaled tobramycin in patients with cystic fibrosis].
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Treatment Outcome | 2010 |
Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Cefepime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Drug Delivery Systems; Drug Design; Dry Powder Inhalers; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Cystic Fibrosis; Dry Powder Inhalers; Humans; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Tobramycin; Treatment Outcome | 2011 |
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections, Intravenous; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Young Adult | 2012 |
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Load; Bayes Theorem; Biological Availability; Chronic Disease; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Information Services; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2012 |
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Ticarcillin; Tobramycin | 2012 |
TOBI: reducing the impact of pseudomonal infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance; Forced Expiratory Volume; Humans; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2002 |
[Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].
Topics: Administration, Inhalation; Adolescent; Aerosols; Anti-Bacterial Agents; Carbenicillin; Child; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Gentamicins; Humans; Nebulizers and Vaporizers; Penicillins; Placebos; Polymyxins; Pseudomonas Infections; Randomized Controlled Trials as Topic; Time Factors; Tobramycin | 2002 |
Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Endocarditis, Bacterial; Humans; Male; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2003 |
Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas Infections; Quality of Life; Tobramycin | 2003 |
Bringing new treatments to the bedside in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxyribonuclease I; Drug Approval; Drug Design; Ethics, Clinical; Genetic Therapy; Humans; Pseudomonas Infections; Tobramycin | 2004 |
Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2002 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2006 |
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Vaccination | 2006 |
Clinical aspects of pseudomonas infections.
Topics: Agammaglobulinemia; Blood Transfusion; Burns; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Endocarditis; Gentamicins; Granulocytes; Humans; Immunosuppression Therapy; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin; Urinary Catheterization; Urologic Diseases | 1981 |
Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis.
Topics: Administration, Inhalation; Aerosols; Bronchial Diseases; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 1995 |
[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchitis; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas Infections; Tobramycin | 1997 |
Use of aerosolized antibiotics in patients with cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacterial Infections; Cystic Fibrosis; Drug Monitoring; Drug Resistance, Microbial; Humans; Patient Selection; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1999 |
Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Bronchoconstriction; Child; Cystic Fibrosis; Drug Administration Schedule; Drug Resistance, Microbial; Environmental Pollution; Gentamicins; Humans; Length of Stay; Licensure; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; United States | 2000 |
Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Endoscopy; Humans; Infant; Nasal Mucosa; Nasal Polyps; Paranasal Sinus Diseases; Pseudomonas Infections; Quality of Life; Recurrence; Tobramycin | 2000 |
Empiric therapy of febrile granulocytopenic patients.
Topics: Agranulocytosis; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Blood Transfusion; Cephalosporins; Drug Therapy, Combination; Gentamicins; Granulocytes; Humans; Klebsiella Infections; Neoplasms; Penicillins; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1979 |
[Aminoglycoside antibiotics from clinical viewpoint].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Drug Combinations; Enterobacteriaceae Infections; Escherichia coli Infections; Gentamicins; Glomerular Filtration Rate; Kanamycin; Klebsiella Infections; Proteus Infections; Providencia; Pseudomonas Infections; Serratia; Sisomicin; Streptomycin; Tobramycin | 1975 |
Shunt infections: prevention and treatment.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cerebrospinal Fluid Shunts; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; Gentamicins; Humans; Injections, Intravenous; Injections, Intraventricular; Klebsiella Infections; Leukocytes; Meningitis; Premedication; Pseudomonas Infections; Reoperation; Rifampin; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin; Vancomycin | 1985 |
Respiratory infections: clinical evaluation.
Topics: Amikacin; Carbenicillin; Cefotaxime; Cystic Fibrosis; Drug Therapy, Combination; Enterobacteriaceae; Haemophilus influenzae; Humans; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Streptococcus; Streptococcus pneumoniae; Tobramycin | 1985 |
126 trial(s) available for tobramycin and Pseudomonas Infections
| Article | Year |
|---|---|
Testing the effects of combining azithromycin with inhaled tobramycin for
Topics: Administration, Inhalation; Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Forced Expiratory Volume; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bronchiectasis; Double-Blind Method; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin | 2023 |
Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Double-Blind Method; Forced Expiratory Volume; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Liposomes; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Surveys and Questionnaires; Symptom Assessment; Symptom Flare Up; Tobramycin; Treatment Outcome | 2020 |
Effect of adjunctive tobramycin inhalation versus placebo on early clinical response in the treatment of ventilator-associated pneumonia: the VAPORISE randomized-controlled trial.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Double-Blind Method; Humans; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2020 |
An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Pilot Projects; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Young Adult | 2020 |
Efficacy and safety of TOBI Podhaler in
Topics: Administration, Inhalation; Adolescent; Adult; Bronchiectasis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2020 |
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Colistin; Cross-Over Studies; Cystic Fibrosis; Equipment Contamination; Equipment Design; Europe; Female; Forced Expiratory Volume; Humans; Lung; Male; Nebulizers and Vaporizers; Patient Satisfaction; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin; Treatment Outcome; Young Adult | 2017 |
Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Biological Availability; Child; Child, Preschool; Computer Simulation; Cystic Fibrosis; Female; Humans; Infant; Male; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2017 |
Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Retrospective Studies; Sputum; Time Factors; Tobramycin; Treatment Outcome | 2019 |
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Time Factors; Tobramycin; Treatment Outcome | 2018 |
Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Male; Maximal Expiratory Flow Rate; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Treatment Outcome; Young Adult | 2013 |
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Female; Hospitalization; Humans; Infant; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Tobramycin; Treatment Outcome | 2013 |
Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.
Topics: Administration, Intravenous; Adult; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Tobramycin; Young Adult | 2013 |
Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Topics: Administration, Inhalation; Adolescent; Age Factors; Anti-Bacterial Agents; Child; Confidence Intervals; Cystic Fibrosis; Dry Powder Inhalers; Female; Forced Expiratory Volume; Humans; Male; Patient Satisfaction; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2014 |
Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Cross-Over Studies; Cystic Fibrosis; Disease Progression; England; Female; Humans; Injections, Intravenous; Kidney; Lung; Male; Nebulizers and Vaporizers; Pilot Projects; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Time Factors; Tobramycin; Treatment Outcome; Young Adult | 2014 |
Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Aerosols; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin; Treatment Outcome | 2014 |
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Interactions; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Young Adult | 2014 |
Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Child; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Nebulizers and Vaporizers; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Therapeutic Equivalency; Tobramycin; Treatment Outcome; Young Adult | 2014 |
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Treatment Outcome; Young Adult | 2015 |
Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cost-Benefit Analysis; Cystic Fibrosis; Female; Humans; Lung Transplantation; Male; Models, Economic; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; United States; Young Adult | 2015 |
Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Serum; Tobramycin; Young Adult | 2016 |
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Humans; Male; Microbial Sensitivity Tests; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin; Treatment Outcome; Young Adult | 2016 |
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
Topics: Administration, Inhalation; Adult; Aerosols; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2016 |
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Medication Therapy Management; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin; Treatment Outcome | 2016 |
Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Cough; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Aztreonam; Cystic Fibrosis; Drug Administration Routes; Drug Interactions; Drug Monitoring; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome; Young Adult | 2017 |
Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pilot Projects; Pseudomonas Infections; Time Factors; Tobramycin; Treatment Outcome | 2008 |
Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
Topics: Administration, Inhalation; Adult; Aerosols; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Cystic Fibrosis; Equipment Design; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Patient Satisfaction; Pilot Projects; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Solutions; Tissue Distribution; Tobramycin; Young Adult | 2008 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic Fibrosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Longitudinal Studies; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tobramycin; Treatment Outcome | 2009 |
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Lung; Lung Diseases; Male; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2009 |
Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2009 |
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2009 |
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infant; Male; Opportunistic Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2010 |
The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Child; Cystic Fibrosis; Female; Humans; Lung; Male; Pilot Projects; Pseudomonas aeruginosa; Pseudomonas Infections; Spirometry; Sputum; Tobramycin; Tomography, X-Ray Computed | 2010 |
Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Cystic Fibrosis; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Ear Diseases; Female; Humans; Injections, Intravenous; Kidney Diseases; Lung; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2011 |
Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adult; Animals; Anti-Bacterial Agents; Biofilms; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung; Male; Microbial Sensitivity Tests; Pilot Projects; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Lew; Tobramycin; Treatment Outcome | 2010 |
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2011 |
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cough; Cystic Fibrosis; Drug Administration Schedule; Drug Delivery Systems; Drug Monitoring; Dry Powder Inhalers; Female; Humans; Male; Middle Aged; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Tobramycin; Treatment Outcome | 2011 |
Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Lung; Male; Nebulizers and Vaporizers; Patient Preference; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2011 |
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Risk; Tobramycin; Treatment Failure | 2012 |
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Infant; Male; Placebos; Proportional Hazards Models; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; United States | 2011 |
Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cough; Cystic Fibrosis; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Fosfomycin; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome; United States | 2012 |
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chi-Square Distribution; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia; Tobramycin; Treatment Outcome | 2012 |
Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Male; Medication Adherence; Nebulizers and Vaporizers; Patient Satisfaction; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Psychometrics; Reproducibility of Results; Surveys and Questionnaires; Tobramycin; Young Adult | 2012 |
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Infant; Male; Prospective Studies; Pseudomonas Infections; Sputum; Tobramycin; Treatment Outcome | 2013 |
Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Child; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2013 |
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Colistin; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Powders; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pseudomonas Infections; Sputum; Tobramycin | 2013 |
Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.
Topics: Administration, Inhalation; Adolescent; Bronchial Hyperreactivity; Bronchoconstriction; Child; Cross-Over Studies; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Pneumonia, Bacterial; Preservatives, Pharmaceutical; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Spirometry; Tobramycin | 2002 |
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Child; Chronic Disease; Colistin; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2002 |
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Topics: Administration, Inhalation; Age Factors; Anti-Bacterial Agents; Audiometry; Bronchoalveolar Lavage Fluid; Carrier State; Child, Preschool; Creatinine; Cystic Fibrosis; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Genotype; Hearing Disorders; Humans; Kidney Diseases; Male; Oropharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Safety; Severity of Illness Index; Sputum; Tobramycin; Treatment Outcome | 2003 |
The long-term use of inhaled tobramycin in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Age Factors; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Time Factors; Tobramycin; Treatment Outcome | 2002 |
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adult; Aged; Anti-Bacterial Agents; Bronchiectasis; Bronchitis, Chronic; Cross-Over Studies; Double-Blind Method; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Quality of Life; Tobramycin | 2005 |
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Female; Humans; Lung Diseases; Male; Middle Aged; Pilot Projects; Pseudomonas Infections; Severity of Illness Index; Solutions; Tobramycin | 2005 |
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Deoxyribonuclease I; Drug Monitoring; Forced Expiratory Volume; Genotype; Heterozygote; Homozygote; Hospitalization; Humans; Pneumonia, Bacterial; Predictive Value of Tests; Proportional Hazards Models; Pseudomonas Infections; Risk Factors; Severity of Illness Index; Tobramycin; Treatment Outcome; United States | 2005 |
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Child; Child, Preschool; Cystic Fibrosis; Disease Progression; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Meropenem; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Thienamycins; Tobramycin | 2005 |
Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Audiometry, Pure-Tone; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Hearing Loss; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2006 |
Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Chronic Disease; Colistin; Cross-Over Studies; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Male; Pseudomonas Infections; Tobramycin | 2006 |
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2006 |
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; United Kingdom; United States | 2006 |
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cough; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Dysgeusia; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Opportunistic Infections; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2007 |
Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study.
Topics: Acinetobacter; Acinetobacter Infections; Administration, Inhalation; Adult; Aged; Anti-Bacterial Agents; APACHE; Creatinine; Double-Blind Method; Female; Hospitals, University; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Organ Failure; Pilot Projects; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2007 |
Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Male; Poland; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2008 |
Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Biological Availability; Chronic Disease; Cross-Over Studies; Cystic Fibrosis; Double-Blind Method; Female; Humans; Male; Nebulizers and Vaporizers; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Therapeutic Equivalency; Tobramycin | 2007 |
Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Humans; Male; Nebulizers and Vaporizers; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2007 |
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2007 |
Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Burkholderia cepacia; Burkholderia Infections; Computer Simulation; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Models, Biological; Nebulizers and Vaporizers; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Respiratory Mechanics; Respiratory System; Sputum; Taurine; Thiadiazines; Tobramycin | 2007 |
Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Pseudomonas Infections; Sputum; Tobramycin | 2007 |
Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial.
Topics: Adult; Aged; Bacterial Infections; Cefotaxime; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Humans; Infusions, Parenteral; Kidney Diseases; Male; Middle Aged; Nafcillin; Penicillin Resistance; Prognosis; Pseudomonas Infections; Random Allocation; Tobramycin; Urinary Tract Infections | 1984 |
Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
Topics: Adolescent; Adult; Carbenicillin; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Penicillin Resistance; Prospective Studies; Pseudomonas Infections; Random Allocation; Respiratory Function Tests; Respiratory Tract Infections; Tobramycin | 1983 |
A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Escherichia coli Infections; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pseudomonas Infections; Random Allocation; Tobramycin; Urinary Tract Infections | 1983 |
Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.
Topics: Adolescent; Adult; Body Surface Area; Child; Clinical Trials as Topic; Cystic Fibrosis; Female; Gentamicins; Glomerular Filtration Rate; Humans; Kinetics; Male; Prospective Studies; Protein Binding; Pseudomonas Infections; Tobramycin | 1984 |
Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
Topics: Adolescent; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Lung Diseases; Piperacillin; Pseudomonas Infections; Tobramycin | 1983 |
Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole.
Topics: Adult; Aged; Agranulocytosis; Bacterial Infections; Blood Urea Nitrogen; Cefamandole; Clostridium Infections; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Ear Diseases; Female; Humans; Infusions, Parenteral; Kidney Diseases; Male; Middle Aged; Neoplasms; Pseudomonas Infections; Tobramycin | 1984 |
Short-course aminoglycoside therapy in patients with spinal cord injury. Standard dose versus low dose.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Humans; Injections, Intramuscular; Kanamycin; Proteus Infections; Providencia; Pseudomonas Infections; Random Allocation; Recurrence; Spinal Cord Injuries; Tobramycin; Urinary Bladder, Neurogenic; Urinary Tract Infections | 1980 |
Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Kanamycin; Kinetics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1982 |
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
Topics: Adult; Animals; Anti-Bacterial Agents; Cystic Fibrosis; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Endocarditis, Bacterial; Female; Gentamicins; Glomerular Filtration Rate; Guinea Pigs; Humans; Male; Netilmicin; Pneumonia; Pseudomonas Infections; Rabbits; Rats; Rats, Inbred Strains; Tobramycin | 1983 |
A clinical comparison of tobramycin and gentamicin sulfate in the treatment of ocular infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Clinical Trials as Topic; Conjunctival Diseases; Double-Blind Method; Female; Gentamicins; Humans; Male; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1981 |
Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
Topics: Adolescent; Aerosols; Bronchitis; Cystic Fibrosis; Double-Blind Method; Female; Humans; Male; Monitoring, Physiologic; Pseudomonas Infections; Respiratory Mechanics; Tobramycin | 1993 |
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Gentamicins; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pseudomonas Infections; Regression Analysis; Risk Factors; Tobramycin | 1996 |
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Arthralgia; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Pneumonia, Bacterial; Prospective Studies; Pseudomonas Infections; Tobramycin; Treatment Outcome | 1997 |
Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
Topics: Administration, Oral; Adolescent; Cartilage; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Ultrasonography | 1997 |
Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anthropometry; Body Composition; Ceftazidime; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Nutritional Status; Opportunistic Infections; Prospective Studies; Pseudomonas Infections; Tobramycin | 1997 |
Chronic otitis media treated topically with ciprofloxacin or tobramycin.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Double-Blind Method; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Otitis Media; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 1997 |
Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Humans; Male; Pharynx; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Tobramycin | 1998 |
[Local treatment of purulent chronic otitis media with ciprofloxacin].
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Otitis Media, Suppurative; Pharmaceutical Solutions; Pseudomonas Infections; Tobramycin | 1998 |
Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Pseudomonas Infections; Sputum; Statistics, Nonparametric; Tobramycin | 1998 |
[Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Topics: Adolescent; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin | 1998 |
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Bronchial Diseases; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Hospitalization; Humans; Infusions, Intravenous; Male; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 1999 |
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aspergillus; Bacteria; Candida albicans; Child; Cystic Fibrosis; Double-Blind Method; Drug Resistance, Microbial; Forced Expiratory Volume; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 1999 |
Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 1999 |
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Humans; Pseudomonas Infections; Tobramycin | 1999 |
Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cohort Studies; Costs and Cost Analysis; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Ontario; Pseudomonas Infections; Quebec; Tobramycin | 2000 |
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Models, Biological; Pseudomonas Infections; Tobramycin | 2000 |
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Pseudomonas Infections; Respiratory Function Tests; Respiratory Tract Infections; Time Factors; Tobramycin; Treatment Outcome | 2001 |
Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.
Topics: Adult; Aerosols; Bronchiectasis; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Pseudomonas Infections; Sputum; Staphylococcal Infections; Tobramycin; Treatment Outcome; Vital Capacity | 2001 |
Microbiological and immunologic considerations with aerosolized drug delivery.
Topics: Aerosols; Child; Colony Count, Microbial; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Long-Term Care; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Opportunistic Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Stenotrophomonas maltophilia; Tobramycin | 2001 |
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Cystic Fibrosis; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Long-Term Care; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2002 |
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Drug Administration Schedule; Forced Expiratory Volume; Humans; Lactams; Maximal Midexpiratory Flow Rate; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Vital Capacity | 2002 |
Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Case-Control Studies; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Infant; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2002 |
Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Nebulizers and Vaporizers; Odds Ratio; Outcome Assessment, Health Care; Pseudomonas Infections; Quality Indicators, Health Care; Retrospective Studies; Tobramycin | 2002 |
A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli.
Topics: Anti-Bacterial Agents; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Gentamicins; Gram-Negative Aerobic Bacteria; Humans; Kidney; Kidney Function Tests; Penicillin Resistance; Penicillins; Pneumonia; Pseudomonas Infections; Sepsis; Ticarcillin; Tobramycin | 1978 |
Therapy of infection in patients with granulocytopenia.
Topics: Agranulocytosis; Amikacin; Anti-Bacterial Agents; Blood Transfusion; Carbenicillin; Cephalothin; Clinical Trials as Topic; Drug Therapy, Combination; Gentamicins; Granulocytes; Humans; Infections; Kidney; Leukocyte Count; Mycoses; Neoplasms; Pseudomonas Infections; Ticarcillin; Tobramycin | 1977 |
Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; Female; Humans; Kanamycin; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Neoplasms; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tobramycin; Urinary Tract Infections | 1977 |
Nebcin in the treatment of experimental Pseudomonas keratitis.
Topics: Animals; Anti-Bacterial Agents; Clinical Trials as Topic; Gentamicins; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1975 |
[Clinical evaluation of combined therapy of ceftazidime and tobramycin for intractable pulmonary infection mainly caused by Pseudomonas aeruginosa].
Topics: Aged; Aged, 80 and over; Ceftazidime; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pneumonia; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1992 |
Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers.
Topics: Adolescent; Adult; Aged; Corneal Ulcer; Double-Blind Method; Drug Carriers; Eye Infections, Bacterial; Female; Follow-Up Studies; Humans; Hyaluronic Acid; Male; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Tobramycin; Treatment Outcome | 1992 |
Aerosol scintigraphy in the assessment of therapy for cystic fibrosis.
Topics: Adult; Bronchodilator Agents; Combined Modality Therapy; Cystic Fibrosis; Double-Blind Method; Female; Humans; Lung; Male; Prospective Studies; Pseudomonas Infections; Radionuclide Imaging; Technetium Tc 99m Pentetate; Ticarcillin; Tobramycin | 1992 |
Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.
Topics: Adult; Bacterial Infections; Bayes Theorem; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Kidney Diseases; Male; Pseudomonas Infections; Software; Tobramycin | 1991 |
Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
Topics: Adolescent; Adult; Cystic Fibrosis; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin | 1991 |
Efficacy of inhaled tobramycin in cystic fibrosis.
Topics: Acute Disease; Administration, Inhalation; Child; Clinical Trials as Topic; Cystic Fibrosis; Humans; Pseudomonas Infections; Retrospective Studies; Tobramycin | 1990 |
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adolescent; Adult; Bronchial Diseases; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Male; Patient Compliance; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Tobramycin | 1989 |
Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
Topics: Ceftazidime; Chronic Disease; Cystic Fibrosis; Drug Combinations; Forced Expiratory Volume; Humans; Leukocyte Count; Lung Diseases; Neutrophils; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin; Vital Capacity | 1989 |
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.
Topics: Administration, Inhalation; Aerosols; Child; Clinical Trials as Topic; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Time Factors; Tobramycin | 1989 |
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Azlocillin; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Liver; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Respiratory Tract Infections; Sputum; Tobramycin; Transaminases | 1988 |
Prevention of colonization and infection in critically ill patients: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anti-Bacterial Agents; Bacteria; Cefotaxime; Child; Colistin; Cross Infection; Digestive System; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Oropharynx; Prospective Studies; Pseudomonas Infections; Random Allocation; Respiratory System; Tobramycin | 1988 |
A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Child; Clinical Trials as Topic; Cloxacillin; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Female; Floxacillin; Humans; Male; Pseudomonas Infections; Tobramycin | 1987 |
Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis.
Topics: Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Half-Life; Humans; Infant; Piperacillin; Pseudomonas Infections; Random Allocation; Respiratory Tract Infections; Sputum; Tobramycin | 1988 |
Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Adult; Ceftazidime; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Random Allocation; Time Factors; Tobramycin | 1986 |
Ciprofloxacin: comparative data in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Penicillin Resistance; Pseudomonas Infections; Tobramycin | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1987 |
Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis.
Topics: Adolescent; Adult; Bacterial Infections; Cefoperazone; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Methicillin; Penicillin Resistance; Penicillins; Pleural Effusion; Pseudomonas Infections; Random Allocation; Ticarcillin; Time Factors; Tobramycin | 1985 |
Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Cystic Fibrosis; Drug Combinations; Female; Gentamicins; Humans; Lung Volume Measurements; Male; Netilmicin; Penicillins; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Ticarcillin; Tobramycin | 1985 |
Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.
Topics: Aged; Ceftazidime; Drug Combinations; Female; Humans; Male; Middle Aged; Penicillins; Pneumonia; Prospective Studies; Pseudomonas Infections; Random Allocation; Sepsis; Ticarcillin; Tobramycin | 1985 |
534 other study(ies) available for tobramycin and Pseudomonas Infections
| Article | Year |
|---|---|
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Risk; Risk Factors | 2007 |
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
Topics: Amino Acid Sequence; Aminoglycosides; beta-Lactamases; Brazil; Carbapenems; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2007 |
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Cefepime; Cephalosporins; Culture Media; Drug Resistance, Multiple; Fluoroquinolones; France; Hospitals, University; Humans; Incidence; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Novobiocin; Ofloxacin; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 2008 |
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; DNA Primers; DNA-Binding Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genes, Bacterial; Humans; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Molecular Sequence Data; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Transcription Factors; Virulence | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Genes, Bacterial; Genetic Variation; Humans; Imipenem; Integrons; Kinetics; Meropenem; Molecular Sequence Data; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Homology, Amino Acid; Spain; Thienamycins | 2008 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Brazil; Ceftriaxone; Clindamycin; Drug Resistance, Multiple, Bacterial; Fatal Outcome; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2009 |
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Levofloxacin; Lung Diseases; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Gene Expression Regulation, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Transcription Factors | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
Topics: Alleles; beta-Lactamases; Conjugation, Genetic; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Norway; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping; Sweden | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Membrane Transport Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Halogenation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrrolidinones; Tetracycline Resistance; Tetracyclines | 2017 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
New
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Cell Survival; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Pyridines; Quinolones; Quorum Sensing; Zebrafish | 2022 |
[Pseudomonas aeruginosa infections in turkey poults and treatment trials with apramycin].
Topics: Animals; Anti-Bacterial Agents; Nebramycin; Poultry Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Turkeys | 1987 |
Effect of iron chelation on anti-pseudomonal activity of doxycycline.
Topics: Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Doxycycline; Drug Synergism; Humans; Iron Chelating Agents; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Exploration of the Pharmacodynamics for Pseudomonas aeruginosa Biofilm Eradication by Tobramycin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
Combined Treatment of 6-Gingerol Analog and Tobramycin for Inhibiting Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Biofilms; Catechols; Cell Line; Cell Proliferation; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Epithelial Cells; Fatty Alcohols; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Respiratory Mucosa; Tobramycin | 2021 |
Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
Topics: Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Salts; Sputum; Tobramycin | 2022 |
Anti-Glomerular Basement Membrane Nephritis Potentially Induced by Nebulized Tobramycin Inhalation.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Female; Humans; Nephritis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
Are trough tobramycin concentrations taken from a central venous catheter accurate enough to safely use?
Topics: Anti-Bacterial Agents; Central Venous Catheters; Cystic Fibrosis; Humans; Pseudomonas Infections; Tobramycin | 2022 |
Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic Fibrosis; Humans; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2022 |
Liquid Crystal Nanoparticles Enhance Tobramycin Efficacy in a Murine Model of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Disease Models, Animal; Liquid Crystals; Mice; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Wound Infection | 2022 |
Topics: Anti-Bacterial Agents; Biofilms; Humans; Microbial Sensitivity Tests; Plankton; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis
Topics: Anti-Bacterial Agents; Biofilms; Ciclopirox; Cystic Fibrosis; Dactinomycin; Drug Repositioning; Extracellular Polymeric Substance Matrix; Fluorouracil; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Ribavirin; Tobramycin | 2022 |
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim | 2022 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Electrochemical Quantification of Tobramycin Retention in
Topics: Anti-Bacterial Agents; Carbon; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
Topics: Anti-Bacterial Agents; Bayes Theorem; Child; Cystic Fibrosis; Drug Monitoring; Humans; Pseudomonas Infections; Tobramycin | 2022 |
Synergistic interaction of cuminaldehyde and tobramycin: a potential strategy for the efficient management of biofilm caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia; Tobramycin | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Fluoroquinolones; Genotype; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Pseudomonas aeruginosa aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2022 |
Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds.
Topics: Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Drug Collateral Sensitivity; Genomics; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Efficacy of Antibiotic Eradication Therapy of Early
Topics: Anti-Bacterial Agents; Arthritis, Psoriatic; Child; Ciliary Motility Disorders; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2023 |
Comparison of Three Eradication Treatment Protocols for Pseudomonas Aeruginosa in Children and Adolescents with Cystic Fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Clinical Protocols; Cystic Fibrosis; Humans; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cross-Sectional Studies; Cystic Fibrosis; Gentamicins; Humans; Pseudomonas Infections; Tobramycin | 2024 |
In the Clear: Long-term pulmonary function benefits associated with Pseudomonas aeruginosa eradication.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Child; Colistin; Cystic Fibrosis; Germany; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2023 |
Inhaled Tobramycin for Treatment of Ventilator-Associated Pneumonia: The Interplay of Patient, Drug, and Device.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Humans; Patients; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Tobramycin | 2022 |
An Amino Acid Substitution in Elongation Factor EF-G1A Alters the Antibiotic Susceptibility of Pseudomonas aeruginosa LasR-Null Mutants.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Humans; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Tobramycin; Trans-Activators | 2023 |
Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Genomics; Gentamicins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tobramycin; United States | 2023 |
The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
Topics: Acute Disease; Amikacin; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Microbial Sensitivity Tests; Pancreatitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2023 |
Anti-Biofilm Enzymes-Assisted Antibiotic Therapy against Burn Wound Infection by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Burns; Communicable Diseases; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Wound Infection | 2023 |
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
Topics: Alginates; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Nitrates; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Colistin; Fosfomycin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Sepsis; Tobramycin | 2023 |
Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Azithromycin; Bacteria; Child; Cystic Fibrosis; Humans; Microbiota; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cough; Cystic Fibrosis; Female; Humans; Male; Powders; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Video Recording; Young Adult | 2019 |
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?
Topics: Agar; Alginates; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Lung; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2019 |
Unwarranted use of intravenous aminoglycosides at UK paediatric cystic fibrosis centres.
Topics: Administration, Intravenous; Aminoglycosides; Anti-Bacterial Agents; Child; Cystic Fibrosis; Health Care Surveys; Hearing Loss; Humans; Inappropriate Prescribing; Kidney Diseases; Pediatrics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; United Kingdom | 2019 |
Genomic and phenotypic comparison of environmental and patient-derived isolates of
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Environmental Microbiology; Genomics; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Antibiotic efficacy varies based on the infection model and treatment regimen for
Topics: Animals; Anti-Bacterial Agents; Colistin; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2020 |
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Stability; Drug Storage; Expectorants; Horses; Mucus; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
In vitro effects of combined iron chelation, antibiotics and matrix disruption on clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Humans; Iron Chelating Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin | 2020 |
Serum-Associated Antibiotic Tolerance in Pediatric Clinical Isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2020 |
Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic-Pharmacodynamic Modeling for Evaluation of Treatments against Chronic
Topics: Animals; Anti-Bacterial Agents; Chronic Disease; Drug Development; Lung; Male; Models, Biological; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections; Tobramycin | 2020 |
Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.
Topics: Alginates; Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Drug Carriers; Drug Design; Drug Therapy, Combination; Ferric Compounds; Humans; Magnetic Fields; Magnetite Nanoparticles; Microbial Sensitivity Tests; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Silver; Surface Properties; Tobramycin | 2020 |
Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Child; Computer Simulation; Cystic Fibrosis; Female; Humans; Hydrodynamics; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas Infections; Tissue Distribution; Tobramycin; Young Adult | 2020 |
Anti-Infectives Restore ORKAMBI
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Benzodioxoles; Bronchi; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Tobramycin | 2020 |
Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength.
Topics: Anti-Bacterial Agents; Binding Sites; Drug Resistance, Multiple, Bacterial; Evolution, Molecular; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Ribosomes; Selection, Genetic; Tigecycline; Tobramycin; Whole Genome Sequencing | 2020 |
Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics.
Topics: Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Polysaccharide-Lyases; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
[Treatment refractory multidrug-resistant bacterial keratitis].
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Humans; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Novel Aminoglycoside-Tolerant Phoenix Colony Variants of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Drug Resistance, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2020 |
Neutrophil extracellular traps may have a dual role in Pseudomonas aeruginosa keratitis.
Topics: Animals; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Extracellular Traps; Keratitis; Male; Mice; Mice, Inbred C57BL; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Colistin; Cystic Fibrosis; Female; Humans; Incidence; Infant; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies; Risk Factors; Tobramycin; Vancomycin; Young Adult | 2020 |
Airway microbiome studies challenge simplistic models of inhaled tobramycin benefit.
Topics: Humans; Microbiota; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2020 |
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
Topics: Acetylcysteine; Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Ciprofloxacin; Curcumin; Cytokines; Drug Carriers; Drug Combinations; Drug Compounding; Expectorants; Freeze Drying; Humans; Inflammation Mediators; Macrophages; Microbial Viability; Mucus; Nanoparticles; Permeability; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Pseudomonas Infections; THP-1 Cells; Tobramycin | 2020 |
The effect of particle size of inhaled tobramycin dry powder on the eradication of Pseudomonas aeruginosa biofilms.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Humans; Particle Size; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Cross-Sectional Studies; Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Therapy; Retrospective Studies; Tobramycin | 2021 |
Intrathecal tobramycin and pausing induction chemotherapy for pediatric acute lymphoblastic leukemia facilitate successful management of disseminated Pseudomonas aeruginosa infection and meningitis.
Topics: Anti-Bacterial Agents; Child; Humans; Induction Chemotherapy; Meningitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Humans; Pseudomonas Infections; Tobramycin | 2021 |
Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2022 |
A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Humans; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2021 |
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms.
Topics: Animals; Biofilms; Disease Models, Animal; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Quorum Sensing; Tobramycin | 2021 |
Impact of a pharmacy technician and pharmacist on time to inhaled tobramycin therapy in a pediatric cystic fibrosis clinic.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Pharmacists; Pharmacy Technicians; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2021 |
Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation.
Topics: Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2021 |
Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model.
Topics: Animals; Anti-Bacterial Agents; Cystic Fibrosis; Pseudomonas Infections; Swine; Tobramycin | 2021 |
The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Proteins; Biofilms; Child; Cystic Fibrosis; Extracellular Polymeric Substance Matrix; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tobramycin | 2021 |
Pseudomonas aeruginosa eradication: Finally moving the needle?
Topics: Child; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2017 |
Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome.
Topics: Administration, Inhalation; Aerosols; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Female; Hospitals, University; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Distress Syndrome; Retrospective Studies; Tobramycin; Treatment Outcome | 2017 |
Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Chronic Disease; Cost-Benefit Analysis; Cystic Fibrosis; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Fumarates; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2017 |
Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Computer Simulation; Cystic Fibrosis; Drug Delivery Systems; Female; Humans; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tobramycin | 2017 |
Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
Topics: Anti-Bacterial Agents; Biofilms; Bronchi; Cells, Cultured; Chemistry, Pharmaceutical; Cystic Fibrosis; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Dry Powder Inhalers; Epithelial Cells; Humans; Nanoparticles; Particle Size; Polyelectrolytes; Polymers; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2017 |
PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chickens; Cystic Fibrosis; Humans; Lung; Microbial Sensitivity Tests; Mucus; Polyethylene Glycols; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Swine; Tobramycin | 2018 |
Spatially dependent alkyl quinolone signaling responses to antibiotics in
Topics: Anti-Bacterial Agents; Biofilms; Humans; Hydroxyquinolines; Mass Spectrometry; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Spectrum Analysis, Raman; Tobramycin | 2018 |
Analysis of two quorum sensing-deficient isolates of Pseudomonas aeruginosa.
Topics: 4-Butyrolactone; Bacterial Proteins; Biofilms; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Genes, Bacterial; Glycolipids; Kanamycin; Oligopeptides; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Quorum Sensing; Sequence Analysis; Sequence Analysis, DNA; Sigma Factor; Tobramycin; Virulence Factors | 2018 |
Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
Topics: Administration, Inhalation; Alanine; Anti-Bacterial Agents; Biofilms; Desiccation; Drug Compounding; Dry Powder Inhalers; Excipients; Humans; Particle Size; Powders; Proline; Pseudomonas aeruginosa; Pseudomonas Infections; Succinic Acid; Tobramycin | 2018 |
Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Dry Powder Inhalers; Humans; Longitudinal Studies; Medication Adherence; Opportunistic Infections; Patient Satisfaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Young Adult | 2018 |
The chemical topology of a bacterial swarm.
Topics: Anti-Bacterial Agents; Humans; Hydroxyquinolines; Mass Spectrometry; Microscopy, Confocal; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Tobramycin | 2018 |
Screening, cloning and expression of a novel alginate lyase gene from P. aeruginosa TAG 48 and its antibiofilm effects on P. aeruginosa biofilm.
Topics: Alginates; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Polysaccharide-Lyases; Pseudomonas aeruginosa; Pseudomonas Infections; Substrate Specificity; Tobramycin; Virulence Factors | 2018 |
Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Biofilms; Epithelial Cells; Erythrocytes; Humans; Microscopy, Confocal; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2018 |
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; Treatment Outcome | 2019 |
Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
Topics: Animals; Anti-Bacterial Agents; Biofilms; Colistin; Colonic Neoplasms; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Dosage Calculations; Drug Therapy, Combination; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2018 |
Decreased Pseudomonas aeruginosa detection in children after separation of pediatric from adult cystic fibrosis clinics: A single center experience.
Topics: Administration, Inhalation; Adult; Ambulatory Care Facilities; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Infant, Newborn; Male; Minnesota; Neonatal Screening; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2018 |
The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
Topics: Anti-Bacterial Agents; Biofilms; Cell Membrane; Child; Drug Synergism; Humans; Infant; Membrane Potentials; Microbial Viability; Oxyclozanide; Permeability; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic Fibrosis; Female; Humans; Male; Outcome and Process Assessment, Health Care; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Time Factors; Tobramycin | 2019 |
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Topics: Administration, Inhalation; Administration, Intravenous; Adult; Anti-Bacterial Agents; Azithromycin; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Young Adult | 2019 |
Pyruvate-depleting conditions induce biofilm dispersion and enhance the efficacy of antibiotics in killing biofilms in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Burns; Culture Media; Disease Models, Animal; Fermentation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pyruvic Acid; Staphylococcus aureus; Swine; Tobramycin | 2019 |
Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.
Topics: Anti-Bacterial Agents; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Cystic fibrosis in the modern therapeutic era: Give the shower a thought!
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Equipment Contamination; Equipment Failure; Equipment Failure Analysis; Humans; Nebulizers and Vaporizers; Pseudomonas Infections; Self Care; Tobramycin | 2019 |
Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Topics: Anti-Bacterial Agents; Biofilms; Cell Line; Cystic Fibrosis; Drug Carriers; Humans; Mucus; Nanoparticles; Peptides; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Treatment with the Pseudomonas aeruginosa Glycoside Hydrolase PslG Combats Wound Infection by Improving Antibiotic Efficacy and Host Innate Immune Activity.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Female; Glycoside Hydrolases; Humans; Immunity, Innate; Mice; Mice, Inbred BALB C; Neutrophils; Phagocytosis; Pseudomonas aeruginosa; Pseudomonas Infections; Reactive Oxygen Species; Swine; Tobramycin; Wound Infection | 2019 |
Host metabolites stimulate the bacterial proton motive force to enhance the activity of aminoglycoside antibiotics.
Topics: Anti-Bacterial Agents; Biofilms; Cells, Cultured; Culture Media, Conditioned; Epithelial Cells; Humans; Lung; Metabolome; Microbial Sensitivity Tests; Proton-Motive Force; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas aeruginosa pulmonary infection in children with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Cohort Studies; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Tobramycin | 2019 |
Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
Topics: Adjuvants, Pharmaceutic; Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Erythrocytes; HEK293 Cells; Heterocyclic Compounds; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Swine; Tobramycin | 2019 |
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage; Ceftazidime; Child, Preschool; Ciprofloxacin; Clavulanic Acids; Cross-Sectional Studies; Cystic Fibrosis; Female; Humans; Infant; Longitudinal Studies; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Aspergillosis; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Ticarcillin; Tobramycin | 2019 |
Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Height; Body Weight; Cystic Fibrosis; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2019 |
Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Burns; Ciprofloxacin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Wound Infection | 2013 |
Comment on: Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model.
Topics: Animals; Anti-Bacterial Agents; Drug Synergism; Female; Foreign Bodies; Peritonitis; Pseudomonas Infections; Quorum Sensing; Tobramycin | 2013 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
Topics: Adult; Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Culture Media; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation Rate; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 2013 |
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Combinations; Fosfomycin; Gene Expression Regulation, Bacterial; Humans; Isoenzymes; Lung; Microbial Sensitivity Tests; Nitrate Reductase; Nitrates; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Transcription, Genetic | 2013 |
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Risk Factors; Secondary Prevention; Tobramycin; Treatment Outcome | 2014 |
Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.
Topics: Agar; Animals; Anti-Bacterial Agents; Bacterial Load; Body Weight; Chemokines; Culture Media; Cytokines; Inflammation; Lung; Lung Diseases; Male; Organ Size; Panax; Plant Extracts; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Tobramycin | 2013 |
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Decision Support Techniques; Dry Powder Inhalers; Humans; Models, Economic; Pneumonia, Bacterial; Probability; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Tobramycin; Young Adult | 2014 |
Activities of tobramycin and polymyxin E against Pseudomonas aeruginosa biofilm-coated medical grade endotracheal tubes.
Topics: Anti-Bacterial Agents; Biofilms; Drug Therapy, Combination; Humans; Intubation, Intratracheal; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2014 |
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clinical Trials as Topic; Colistin; Cystic Fibrosis; Drug Monitoring; Drug Therapy, Combination; Dry Powder Inhalers; Humans; Practice Guidelines as Topic; Pseudomonas Infections; Respiratory Function Tests; Respiratory Tract Infections; State Medicine; Tobramycin; United Kingdom | 2013 |
The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa.
Topics: Anaerobiosis; Anti-Bacterial Agents; Biofilms; Cation Transport Proteins; Drug Resistance, Bacterial; Heme; Iron; Iron Chelating Agents; Minocycline; Pseudomonas aeruginosa; Pseudomonas Infections; Siderophores; Tigecycline; Tobramycin | 2014 |
Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Disease Models, Animal; Drug Delivery Systems; Fluorocarbons; Lung; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Surface Tension; Time Factors; Tobramycin; Viscosity | 2014 |
Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Intravenous; Anti-Bacterial Agents; Child, Preschool; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Treatment Outcome | 2014 |
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Failure | 2014 |
Practice guidelines, clinical trials, and unexpected results in cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2014 |
Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
Topics: Administration, Cutaneous; Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Diagnostic Errors; Dry Powder Inhalers; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Skin; Tobramycin; Young Adult | 2014 |
Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Cohort Studies; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Medication Adherence; Middle Aged; Nebulizers and Vaporizers; Patient Satisfaction; Pseudomonas aeruginosa; Pseudomonas Infections; Surveys and Questionnaires; Tobramycin; Treatment Outcome; Young Adult | 2014 |
Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Drug Approval; Drug Interactions; Forced Expiratory Volume; Humans; Pseudomonas Infections; Tobramycin | 2014 |
Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Ceftazidime; Cystic Fibrosis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Genes, MDR; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Sequence Data; Multilocus Sequence Typing; Oxazolidinones; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; RNA, Ribosomal, 23S; Sequence Analysis, DNA; Staphylococcal Infections; Tobramycin | 2014 |
Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.
Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Metalloproteases; Microbial Sensitivity Tests; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Sputum; Tobramycin; Virulence Factors | 2014 |
Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
Topics: Anti-Bacterial Agents; Colistin; Drug Carriers; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Osteomyelitis; Plasma; Polymethyl Methacrylate; Pseudomonas aeruginosa; Pseudomonas Infections; Synovial Fluid; Tobramycin; Treatment Outcome | 2014 |
Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
Topics: Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Meropenem; Microbial Sensitivity Tests; Monocytes; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2015 |
Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Topics: Adult; Alginates; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Chitosan; Cystic Fibrosis; Deoxyribonuclease I; DNA; Glucuronic Acid; Hexuronic Acids; Humans; Microbial Sensitivity Tests; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sputum; Tobramycin; Treatment Outcome | 2015 |
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Aztreonam; Child; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Treatment Outcome; Young Adult | 2015 |
A demonstration of the susceptibility of clinical isolates obtained from cystic fibrosis patients to manuka honey.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia; Burkholderia Infections; Colistin; Cystic Fibrosis; Honey; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clinical Trials as Topic; Cystic Fibrosis; Drug Combinations; Fosfomycin; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2015 |
In Vivo Efficacy of Antimicrobials against Biofilm-Producing Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Biofilms; Cell Line, Tumor; Colistin; Cystic Fibrosis; Disease Models, Animal; Female; Lung Diseases; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clinical Trials as Topic; Cystic Fibrosis; Dry Powder Inhalers; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Canada; Child; Child, Preschool; Cross-Sectional Studies; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Gene Deletion; Humans; Locomotion; Male; Microbial Sensitivity Tests; Phenotype; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Tobramycin; Treatment Failure | 2016 |
Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
Topics: Biofilms; Cystic Fibrosis; Humans; Lung; Mannitol; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Evolution of metabolic divergence in Pseudomonas aeruginosa during long-term infection facilitates a proto-cooperative interspecies interaction.
Topics: Anti-Bacterial Agents; Biological Evolution; Coculture Techniques; Coinfection; Host-Pathogen Interactions; Humans; Microbial Interactions; Models, Biological; Mutagenesis, Insertional; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Virulence Factors | 2016 |
Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis.
Topics: Administration, Inhalation; Animals; Cystic Fibrosis; Drug Carriers; Drug Delivery Systems; Female; Humans; Lipids; Mice; Mice, Inbred BALB C; Nanostructures; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Topics: Amides; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Lung; Microscopy, Confocal; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidines; Quorum Sensing; Respiratory Tract Infections; Tobramycin | 2015 |
Structural Analysis of the Tobramycin and Gentamicin Clinical Resistome Reveals Limitations for Next-generation Aminoglycoside Design.
Topics: Adenosine Triphosphate; Aminoglycosides; Anti-Bacterial Agents; Drug Design; Drug Resistance, Bacterial; Gentamicins; Humans; Manganese; Models, Molecular; Molecular Docking Simulation; Nucleotidyltransferases; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
Topics: Anti-Bacterial Agents; Aztreonam; Biofilms; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2016 |
[SUCCESSFUL TREATMENT OF ACUTE PULMONARY ABSCESS IN AN ELDERLY PATIENT].
Topics: Acute Disease; Administration, Inhalation; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Lung Abscess; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Drug Resistance, Bacterial; Fosfomycin; Humans; Microbial Viability; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Pseudomonas aeruginosa Infection in a Group of Captive Humboldt Penguins ( Spheniscus humboldti ).
Topics: Administration, Oral; Animals; Animals, Zoo; Anti-Bacterial Agents; Antifungal Agents; Bird Diseases; Fatal Outcome; Female; Fluoroquinolones; Itraconazole; Male; Neuroprotective Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Silymarin; Spheniscidae; Tobramycin; Xanthines | 2016 |
Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.
Topics: Animals; Anti-Bacterial Agents; Bacteriocins; Disease Models, Animal; Female; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocins; Species Specificity; Tobramycin | 2016 |
Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
Topics: ADP Ribose Transferases; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Chaperonin 60; Chronic Disease; Ciprofloxacin; Drug Resistance, Bacterial; Female; Genotype; Glucosyltransferases; GTPase-Activating Proteins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Otitis Media; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Tobramycin; Type III Secretion Systems; Virulence Factors | 2017 |
Sequential Inhalational Tobramycin-Colistin-Combination in CF-Patients with Chronic P. Aeruginosa Colonization - an Observational Study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Colistin; Cystic Fibrosis; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2016 |
Development of a Novel Collagen Wound Model To Simulate the Activity and Distribution of Antimicrobials in Soft Tissue during Diabetic Foot Infection.
Topics: Anti-Bacterial Agents; Biofilms; Calcium Sulfate; Collagen; Diabetic Foot; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Staphylococcal Infections; Tobramycin; Vancomycin; Wound Infection | 2016 |
Epigallocatechin Gallate Remodels Overexpressed Functional Amyloids in Pseudomonas aeruginosa and Increases Biofilm Susceptibility to Antibiotic Treatment.
Topics: Amyloid; Bacterial Proteins; Benzothiazoles; Biofilms; Catechin; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Thiazoles; Tobramycin | 2016 |
Improving inhaled antibiotic treatment - Practice defeats the proof.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Pseudomonas Infections; Tobramycin | 2016 |
Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Drug Carriers; Drug Liberation; Epithelial Cells; Humans; Mannitol; Mucus; Nanocomposites; Polyelectrolytes; Polymers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2017 |
Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Bulgaria; Child; Child, Preschool; Cystic Fibrosis; Disk Diffusion Antimicrobial Tests; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin; Young Adult | 2016 |
Effects of loading concentration, blood and synovial fluid on antibiotic release and anti-biofilm activity of bone cement beads.
Topics: Anti-Bacterial Agents; Biofilms; Bone Cements; Calcium Sulfate; Drug Carriers; Humans; Polymethyl Methacrylate; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Vancomycin | 2017 |
In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Topics: Amiloride; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug Interactions; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Membrane Transport Modulators; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2008 |
Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Caloric Tests; Cohort Studies; Cystic Fibrosis; Dizziness; Dose-Response Relationship, Drug; Electronystagmography; Female; Humans; Male; Meniere Disease; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas Infections; Tobramycin; Vestibular Diseases; Vestibule, Labyrinth | 2009 |
In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Colony Count, Microbial; Drug Therapy, Combination; Humans; Infusions, Intravenous; Lung; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas Infections; Rabbits; Spleen; Tobramycin | 2008 |
Devastating outcome after only 6 hours of contact lens wear.
Topics: Adult; Anti-Bacterial Agents; Cephalothin; Contact Lenses, Hydrophilic; Drug Combinations; Female; Gentamicins; Humans; Keratitis; Ointments; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Visual Acuity | 2008 |
Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
Topics: Anti-Bacterial Agents; Benzoates; Biofilms; Cells, Cultured; Conalbumin; Cystic Fibrosis; Deferasirox; Deferoxamine; Epithelial Cells; Humans; Iron Chelating Agents; Pseudomonas Infections; Tobramycin; Triazoles; United States; United States Food and Drug Administration | 2009 |
Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epidemiologic Methods; Female; Genotype; Humans; Lung; Male; Mutation; Pseudomonas Infections; Radiopharmaceuticals; Respiratory Therapy; Technetium; Tobramycin; Young Adult | 2009 |
A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Utilization; Health Care Surveys; Hospitals; Humans; Pediatrics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; United States | 2009 |
[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo].
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cornea; Corneal Stroma; Corneal Ulcer; Data Interpretation, Statistical; Disease Models, Animal; Female; Gentamicins; Ofloxacin; Prospective Studies; Pseudomonas Infections; Rabbits; Tobramycin; Treatment Outcome | 2009 |
Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Encephalitis; Humans; Imipenem; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia; Burkholderia Infections; Child; Child, Preschool; Ciprofloxacin; Colistin; Cystic Fibrosis; Europe; Guideline Adherence; Humans; Infection Control; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Surveys and Questionnaires; Tobramycin; Young Adult | 2009 |
The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child, Preschool; Chronic Disease; Ciprofloxacin; Clavulanic Acids; Colistin; Cost of Illness; Cystic Fibrosis; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins; Ticarcillin; Tobramycin | 2009 |
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Critical Pathways; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Observation; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Targeting a bacterial stress response to enhance antibiotic action.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; DNA Transposable Elements; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Genes, Bacterial; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutagenesis, Insertional; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence | 2009 |
[Ochrobactrum anthropi bacteremia in a child with cystic fibrosis].
Topics: Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Catheterization, Central Venous; Child; Cholecystitis; Cystic Fibrosis; Disease Susceptibility; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Ochrobactrum anthropi; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2010 |
Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Chemokine CXCL2; Colony Count, Microbial; Cystic Fibrosis; Disease Models, Animal; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung; Mice; Mice, Inbred BALB C; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index; Time Factors; Tobramycin | 2009 |
Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2010 |
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fosfomycin; Genetic Fitness; Imipenem; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2010 |
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Bacterial; Eye Infections, Bacterial; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Vancomycin | 2010 |
Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Child; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sputum; Tobramycin; Young Adult | 2010 |
Antibacterial analysis of a zinc-based glass polyalkenoate cement.
Topics: Anti-Bacterial Agents; Bone Cements; Escherichia coli; Escherichia coli Infections; Glass Ionomer Cements; Humans; Kyphoplasty; Materials Testing; Methylmethacrylate; Pseudomonas aeruginosa; Pseudomonas Infections; Spinal Diseases; Surgical Wound Infection; Tobramycin; Vertebroplasty; Zinc | 2011 |
Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Topics: Acute Kidney Injury; Aminoglycosides; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; DNA, Mitochondrial; Drug Administration Schedule; Genetic Predisposition to Disease; Gentamicins; Hearing Loss, Sensorineural; Humans; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Insufficiency; Tobramycin | 2010 |
A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
Topics: Anti-Bacterial Agents; Bacteremia; Bile Duct Diseases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Liver Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2010 |
In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients.
Topics: Administration, Inhalation; Albumins; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Humans; Leukocyte Elastase; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections; Tobramycin | 2010 |
Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Managed Care Programs; Models, Economic; Patient Admission; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; United States | 2010 |
Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Biofilms; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Genetic Variation; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tobramycin | 2011 |
Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; Chronic Disease; Cluster Analysis; Colistin; Cystic Fibrosis; DNA Fingerprinting; Drug Resistance, Bacterial; Female; Genotype; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2010 |
The effectiveness of an improved combination therapy for experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Cornea; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Eye Infections, Bacterial; Keratitis; Polysaccharides, Bacterial; Prednisolone; Pseudomonas Infections; Rabbits; Tobramycin | 2010 |
Adherence with tobramycin inhaled solution and health care utilization.
Topics: Adolescent; Adult; Child; Cystic Fibrosis; Female; Health Services; Hospitalization; Humans; Male; Medication Adherence; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Young Adult | 2011 |
Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
Topics: Administration, Inhalation; Ambulatory Care; Anti-Bacterial Agents; Bronchitis, Chronic; Colistin; Cystic Fibrosis; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2011 |
Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Bulgaria; Child; Cystic Fibrosis; Female; Humans; Male; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Sputum; Tobramycin; Young Adult | 2010 |
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia complex; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Colistin; Cystic Fibrosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Health Care Costs; Health Resources; Humans; Infant; Injections, Intravenous; Nebulizers and Vaporizers; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2011 |
Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Formularies, Hospital as Topic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Topics: Ceftazidime; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2011 |
Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Insufficiency, Chronic; Tobramycin | 2011 |
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Deoxyribonuclease I; Female; Humans; Longitudinal Studies; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2012 |
What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Costs and Cost Analysis; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Longitudinal Studies; Male; Managed Care Programs; Middle Aged; Pseudomonas Infections; Retrospective Studies; Tobramycin; Young Adult | 2011 |
Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Humans; Lung; Mesocricetus; Muramidase; Neutrophils; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Tobramycin | 2011 |
Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Iron; Microbial Sensitivity Tests; Oxygen; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract; Urinary Tract Infections | 2012 |
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Western; Cefepime; Cephalosporins; Computer Simulation; Drug Administration Schedule; Drug Interactions; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tobramycin | 2012 |
Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Cystic Fibrosis; Follow-Up Studies; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rhinitis; Sinusitis; Tobramycin; Treatment Outcome | 2011 |
Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
Topics: Anti-Bacterial Agents; Biofilms; Colony Count, Microbial; Cystic Fibrosis; Drug Combinations; Fosfomycin; Humans; Lung; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 2012 |
Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2011 |
Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Foreign Bodies; Histocytochemistry; Mice; Mice, Inbred BALB C; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Tobramycin | 2012 |
Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chemical Fractionation; Disulfides; Drug Synergism; Garlic; Gene Expression Regulation, Bacterial; Genes, Reporter; Glycolipids; Mice; Neutrophils; Plant Extracts; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Respiratory Tract Infections; Sulfoxides; Tobramycin; Virulence Factors | 2012 |
Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Inhalation; Aerosols; Anti-Bacterial Agents; APACHE; Bronchoalveolar Lavage; Colistin; Comorbidity; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tobramycin; Treatment Outcome | 2012 |
The carbon monoxide releasing molecule CORM-2 attenuates Pseudomonas aeruginosa biofilm formation.
Topics: Anti-Bacterial Agents; Biofilms; Carbon Monoxide; Epithelial Cells; Humans; Organometallic Compounds; Pseudomonas aeruginosa; Pseudomonas Infections; Reactive Oxygen Species; Tobramycin | 2012 |
In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
Topics: Anti-Bacterial Agents; Aztreonam; Biofilms; Cystic Fibrosis; Epithelial Cells; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 2012 |
Aerosolized antibiotic therapy: a forward aerial assault or forced contingency for ventilator-associated pneumonia?
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Female; Humans; Male; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Tobramycin | 2012 |
Aztreonam for inhalation solution, challenges to drug approval and integration into CF care.
Topics: Anti-Bacterial Agents; Aztreonam; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Tobramycin | 2013 |
Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy.
Topics: Alginates; Amino Acids; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Drug Combinations; Drug Synergism; Escherichia coli; Glucuronic Acid; Hexuronic Acids; Humans; Kinetics; Microscopy, Electron, Scanning; Polysaccharide-Lyases; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Serum Albumin, Bovine; Tobramycin | 2013 |
Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.
Topics: Acyl-Butyrolactones; Administration, Inhalation; Animals; Anti-Bacterial Agents; Biological Availability; Bismuth; Drug Compounding; Kidney; Liposomes; Lung; Mercaptoethanol; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Rats; Respiratory Tract Infections; Tobramycin; Treatment Outcome; Virulence Factors | 2013 |
[Effects of Imipenem, Tobramycin and Curcumin on Biofilm Formation of Pseudomonas aeruginosa Strains].
Topics: Anti-Bacterial Agents; Biofilms; Curcumin; Cystic Fibrosis; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2013 |
Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Topics: Acute Kidney Injury; Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 2002 |
Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Registries; Risk Factors; Selection Bias; Tobramycin; United States | 2003 |
Antibiotic bone cement for the treatment of Pseudomonas aeruginosa in joint arthroplasty: comparison of tobramycin and gentamicin-loaded cements.
Topics: Anti-Bacterial Agents; Bone Cements; Gentamicins; Humans; In Vitro Techniques; Joint Prosthesis; Microbial Sensitivity Tests; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
Orthokeratology lens-related Pseudomonas aeruginosa infectious keratitis.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Contact Lenses; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Humans; Male; Myopia; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Visual Acuity | 2003 |
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Topics: Anti-Bacterial Agents; Ceftazidime; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Injections, Intravenous; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Retrospective Studies; Sputum; Tobramycin | 2003 |
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
Topics: Amikacin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
Ecthyma gangrenosum arising from Pseudomonas aeruginosa dacryocystitis.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Dacryocystitis; Dacryocystorhinostomy; Debridement; Drug Therapy, Combination; Ecthyma; Eye Infections, Bacterial; Eyelid Diseases; Female; Gangrene; Humans; Intubation; Pseudomonas Infections; Skin; Tobramycin; Tomography, X-Ray Computed | 2003 |
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Resistance, Bacterial; Gentamicins; Humans; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cornea; Corneal Ulcer; Disease Models, Animal; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Glucocorticoids; Mice; Mice, Inbred C57BL; Ofloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
Inhaled antibiotics.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Cystic Fibrosis; Humans; Nebulizers and Vaporizers; Pseudomonas Infections; Tobramycin | 2004 |
Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
Topics: Ceftazidime; Ciprofloxacin; Culture Media, Conditioned; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Tobramycin | 2004 |
Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactam Resistance; Ceftazidime; Ciprofloxacin; Colorado; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Hospitals, Teaching; Hospitals, Urban; Humans; Imipenem; Incidence; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sentinel Surveillance; Tobramycin | 2004 |
Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2004 |
Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Female; Humans; Kidney Failure, Chronic; Pseudomonas Infections; Renal Dialysis; Tobramycin; Vestibular Diseases; Vestibular Function Tests | 2004 |
New clinical evidence from the European tobramycin trial in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Europe; Humans; Lung Diseases; Nebulizers and Vaporizers; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2002 |
Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Colistin; Cystic Fibrosis; Europe; Humans; Lung Diseases; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2002 |
Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Hospital Costs; Humans; Male; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin | 2003 |
Isolation of an amikacin-resistant Escherichia coli strain after tobramycin treatment of previous recurrent episodes of respiratory tract infections caused by Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Respiratory Tract Infections; Tobramycin | 2005 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2004 |
Evaluation on the use of beta-lactamase and aminoglycoside modifying enzyme gene sequences as markers for the early detection of antibiotic resistance profile of Pseudomonas aeruginosa.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Biomarkers; Biotin; Blotting, Southern; Cross Infection; DNA; DNA Primers; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Electrophoresis, Agar Gel; Gentamicins; Humans; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Penicillins; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Sequence Analysis, DNA; Streptomycin; Tobramycin | 2004 |
Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Injections, Intravenous; Lung Diseases; Male; Nephelometry and Turbidimetry; Pseudomonas aeruginosa; Pseudomonas Infections; Saliva; Tobramycin | 2004 |
Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Cystic Fibrosis; DNA-Binding Proteins; Female; Gene Expression Regulation, Bacterial; Humans; Hydrogen Peroxide; Mice; Mice, Inbred BALB C; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Signal Transduction; Tobramycin; Trans-Activators; Virulence | 2005 |
[Case reports of the treatment with tobramycin solution for inhalation in severe bronchiectasis patients continuous infection of Pseudomonas aeruginosa].
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Bronchitis; Chronic Disease; Female; Humans; Middle Aged; Pseudomonas Infections; Respiratory Therapy; Tobramycin | 2005 |
Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ceftazidime; Colorimetry; Cystic Fibrosis; Drug Therapy, Combination; Formazans; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Antibiotic tolerance induced by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Lactoferrin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Inhaled tobramycin: not just for cystic fibrosis anymore?
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Cystic Fibrosis; Humans; Lung Diseases; Pseudomonas Infections; Tobramycin | 2005 |
Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Child; Cystic Fibrosis; Forced Expiratory Volume; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin; Vital Capacity | 2005 |
Infectious keratitis after astigmatic keratotomy in penetrating keratoplasty: review of three cases.
Topics: Astigmatism; Cefazolin; Cornea; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fuchs' Endothelial Dystrophy; Humans; Keratitis; Keratitis, Herpetic; Keratoplasty, Penetrating; Keratotomy, Radial; Male; Middle Aged; Postoperative Complications; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 2005 |
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Female; Humans; Lung Transplantation; Middle Aged; Pseudomonas Infections; Renal Insufficiency; Tobramycin; Vestibular Diseases | 2005 |
Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Tobramycin | 2005 |
Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Oxygen; Plankton; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1989 |
Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms.
Topics: Anaerobiosis; Anti-Bacterial Agents; Arginine; Biofilms; Drug Synergism; Nitrates; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2006 |
Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Ceftazidime; Cystic Fibrosis; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thienamycins; Tobramycin | 2006 |
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Female; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2006 |
Pseudomonas keratitis after laser in situ keratomileusis.
Topics: Adult; Anti-Bacterial Agents; Cefazolin; Cephalosporin Resistance; Ciprofloxacin; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Kanamycin Resistance; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Postoperative Complications; Pseudomonas Infections; Tobramycin | 2006 |
In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Proteins; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2006 |
Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2006 |
Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; Infant, Newborn; Infusions, Intravenous; Male; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Prenatal Diagnosis; Pseudomonas Infections; Tobramycin | 2006 |
Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Child; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Pseudomonas Infections; Sputum; Tobramycin | 2007 |
Acute renal failure associated with inhaled tobramycin.
Topics: Acute Kidney Injury; Administration, Inhalation; Anti-Bacterial Agents; Female; Humans; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2006 |
Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa.
Topics: Acute Kidney Injury; Administration, Inhalation; Aged; Anti-Bacterial Agents; Colony Count, Microbial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Radiography, Thoracic; Tobramycin | 2006 |
Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Biofilms; Colony Count, Microbial; Female; Microscopy, Electron, Scanning; Mucous Membrane; Pseudomonas; Pseudomonas Infections; Rabbits; Sinusitis; Therapeutic Irrigation; Tobramycin | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia Infections; Serratia marcescens; Tobramycin | 2007 |
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Solutions; Time Factors; Tobramycin | 2007 |
A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Chlorhexidine; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Animal; Drug Combinations; Eye Infections, Bacterial; Keratitis; Microbial Sensitivity Tests; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin | 2007 |
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Confidence Intervals; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Humans; Incidence; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Tobramycin; United States | 2007 |
Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
Topics: Anti-Bacterial Agents; Biofilms; Ceftazidime; Cystic Fibrosis; Humans; Hydrogen-Ion Concentration; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2007 |
[The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2007 |
Tobramycin-induced hepatotoxicity.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Chemical and Drug Induced Liver Injury; Female; Humans; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2007 |
Pseudomonas keratitis associated with daily wear of silicone hydrogel contact lenses.
Topics: Adolescent; Anti-Bacterial Agents; Cefazolin; Contact Lenses, Hydrophilic; Corneal Ulcer; Cyclopentolate; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Silicone Elastomers; Tobramycin | 2008 |
The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.
Topics: Anti-Bacterial Agents; Biofilms; Cells, Cultured; Coculture Techniques; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Resistance, Microbial; Epithelial Cells; Humans; Iron; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Mucosa; Tobramycin | 2008 |
Pharmacokinetic variability of extended interval tobramycin in burn patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Burns; Creatinine; Critical Care; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas Infections; Tobramycin; Treatment Outcome; Wound Infection | 2008 |
Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
Topics: Animals; Anti-Bacterial Agents; Dexamethasone; Disease Models, Animal; Drug Compounding; Eye Infections, Bacterial; Keratitis; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Random Allocation; Tobramycin; Treatment Outcome | 2008 |
Cystic fibrosis: ironing out the problem of infection?
Topics: Anti-Bacterial Agents; Biofilms; Cells, Cultured; Coculture Techniques; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Resistance, Microbial; Epithelial Cells; Humans; Iron; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Mucosa; Tobramycin | 2008 |
[Trobramycin by inhalation].
Topics: Administration, Inhalation; Adult; Aminoglycosides; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2008 |
Infection in a puncture wound after it 'healed'.
Topics: Child; Foot Injuries; Humans; Male; Osteomyelitis; Pseudomonas Infections; Ticarcillin; Tobramycin; Wound Infection; Wounds, Penetrating | 1983 |
Amikacin, gentamicin and tobramycin resistant Pseudomonas aeruginosa in a leukaemic ward. Epidemiology and genetic studies.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Drug Resistance, Microbial; Female; Gentamicins; Humans; Leukemia; Male; Middle Aged; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1982 |
Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs.
Topics: Animals; Cefoperazone; Cefsulodin; Ceftazidime; Cephalosporins; Cephamycins; Drug Evaluation, Preclinical; Guinea Pigs; Moxalactam; Pneumonia; Pseudomonas Infections; Ticarcillin; Tobramycin | 1982 |
[Therapy of "malignant otitis externa"].
Topics: Aminoglycosides; Diabetes Complications; Diabetes Mellitus; Humans; Hyperbaric Oxygenation; Otitis Externa; Penicillins; Piperacillin; Pseudomonas Infections; Tobramycin | 1983 |
Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Cephalosporins; Cephamycins; Child; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Male; Moxalactam; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1983 |
[Pseudomonas aeruginosa meningitis treated with azlocillin. 5 cases].
Topics: Adolescent; Adult; Aged; Amikacin; Azlocillin; Drug Therapy, Combination; Female; Humans; Male; Meningitis; Middle Aged; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1984 |
Synergism of ceftizoxime and tobramycin for Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Ceftizoxime; Drug Synergism; Drug Therapy, Combination; Humans; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1982 |
In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Cefotaxime; Ceftriaxone; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Gentamicins; Kanamycin; Leukopenia; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Half-Life; Humans; Kinetics; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Tobramycin | 1983 |
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
Topics: Adolescent; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Sulfamethoxazole; Tobramycin; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1983 |
Ceftazidime - a significant advance in the treatment of cystic fibrosis.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Floxacillin; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Tobramycin | 1983 |
Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Escherichia coli Infections; Female; Fever; Humans; Klebsiella Infections; Leukemia; Lung Neoplasms; Lymphoma; Male; Middle Aged; Moxalactam; Neutropenia; Pseudomonas Infections; Sarcoma; Ticarcillin; Tobramycin | 1984 |
Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.
Topics: Animals; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Guinea Pigs; Kidney; Liver; Male; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Spleen; Ticarcillin; Tobramycin | 1983 |
Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Female; Gentamicins; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
[Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
Topics: Animals; Anti-Bacterial Agents; Bacterial Vaccines; Burns; Drug Evaluation, Preclinical; Histocytochemistry; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1983 |
Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.
Topics: Adult; Auditory Threshold; Creatinine; Endocarditis, Bacterial; Female; Gentamicins; Hearing Loss; Hearing Loss, Bilateral; Humans; Kidney Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1984 |
Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model.
Topics: Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endotoxins; Exotoxins; Female; Mice; Microbial Sensitivity Tests; Neutropenia; Penicillin Resistance; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 1984 |
Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
Topics: Agranulocytosis; Aminoglycosides; Animals; Anti-Bacterial Agents; Azlocillin; Ceftazidime; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Guinea Pigs; Netilmicin; Neutropenia; Penicillin Resistance; Penicillins; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1984 |
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Guinea Pigs; Kinetics; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Ticarcillin; Tobramycin | 1984 |
The effects of antibiotic-supplemented bone allografts on contaminated, partially avulsive fractures of the canine ulna.
Topics: Animals; Bone Transplantation; Cephalothin; Dogs; Male; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Tissue Preservation; Tobramycin; Ulna; Ulna Fractures; Wound Healing | 1984 |
Gentamicin-resistant Pseudomonas aeruginosa corneal ulcers.
Topics: Adult; Aged; Child; Corneal Ulcer; Drug Resistance, Microbial; Female; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1984 |
Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.
Topics: Anti-Bacterial Agents; Azlocillin; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Tobramycin | 1982 |
Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients.
Topics: Adult; Anti-Bacterial Agents; Carbenicillin; Drug Therapy, Combination; Gentamicins; Humans; Male; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 1984 |
Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Azlocillin; Aztreonam; Guinea Pigs; Penicillins; Piperacillin; Pneumonia; Pseudomonas Infections; Ticarcillin; Tobramycin | 1984 |
Osteomyelitis of an epiphyseal region.
Topics: Adolescent; Drainage; Drug Therapy, Combination; Follow-Up Studies; Foot Diseases; Humans; Length of Stay; Male; Nafcillin; Osteomyelitis; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Ticarcillin; Time Factors; Tobramycin; Toes | 1983 |
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
Topics: Adult; Anti-Bacterial Agents; Carbenicillin; Cefsulodin; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Peak Expiratory Flow Rate; Pseudomonas Infections; Tobramycin | 1983 |
Azlocillin in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Penicillins; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1983 |
[Chemotherapeutic effectiveness of gentamycin, tobramycin and sisomycin in Pseudomonas aeruginosa pyelonephritis in rats compared with dioxidine].
Topics: Animals; Anti-Infective Agents; Drug Evaluation, Preclinical; Female; Gentamicins; Pseudomonas Infections; Pyelonephritis; Quinoxalines; Rats; Sisomicin; Time Factors; Tobramycin | 1984 |
Combined gentamicin-tobramycin-corticosteroid treatment. II. Effect on gentamicin-resistant Pseudomonas keratitis.
Topics: Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gentamicins; Keratitis; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Time Factors; Tobramycin; Triamcinolone Acetonide | 1980 |
Relative efficacy of the topical use of amikacin, gentamicin and tobramycin in experimental Pseudomonas keratitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Disease Models, Animal; Gentamicins; Guinea Pigs; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1980 |
Distribution of Pseudomonas aeruginosa serotypes in bacteriologic specimens and their aminoglycoside resistance.
Topics: Amikacin; Aminoglycosides; Drug Resistance, Microbial; Female; Gentamicins; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping; Sisomicin; Tobramycin | 1980 |
A long-term study of gentamicin-resistant Pseudomonas aeruginosa in a general hospital.
Topics: Amikacin; Cross Infection; Drug Resistance, Microbial; Gentamicins; Hospitals, General; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1981 |
Sisomicin: an aminoglycoside antibiotic that is highly effective against Pseudomonas.
Topics: Amikacin; Animals; Carbenicillin; Gentamicins; Humans; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sisomicin; Ticarcillin; Tobramycin | 1981 |
Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs.
Topics: Animals; Bacterial Vaccines; Guinea Pigs; Lipopolysaccharides; Lung Diseases; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1981 |
Are measurements of urine enzymes useful during aminoglycoside therapy?
Topics: Acetylglucosaminidase; Adolescent; Adult; alpha-L-Fucosidase; Aminoglycosides; beta-Galactosidase; Child; Child, Preschool; Cystic Fibrosis; Female; Gentamicins; Glycoside Hydrolases; Humans; Kidney; Lung Diseases; Male; Middle Aged; Muramidase; Pseudomonas Infections; Tobramycin | 1981 |
Plasmid-determined tobramycin and gentamicin resistance in strains of Pseudomonas aeruginosa from two Sydney hospitals.
Topics: Anti-Bacterial Agents; Australia; Cross Infection; Gentamicins; Hospitals; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Streptomycin; Sulfonamides; Tobramycin | 1981 |
In vivo inactivation of tobramycin by ticarcillin. A case report.
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Half-Life; Humans; Kidney; Kinetics; Lung; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1982 |
Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Azlocillin; Drug Therapy, Combination; Osteomyelitis; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1982 |
Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Guinea Pigs; Imipenem; Male; Penicillins; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Ticarcillin; Tobramycin | 1982 |
Gentamicin and tobramycin penetration into burn eschar. Pharmacokinetics and microbiological effects.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Burns; Drug Therapy, Combination; Female; Gentamicins; Humans; Injections, Intravenous; Male; Middle Aged; Pseudomonas Infections; Tobramycin | 1983 |
Usefulness of intraventricular and intrathecal antibiotic therapy in a case of "Pseudomonas aeruginosa" induced long-term meningitis.
Topics: Adolescent; Anti-Bacterial Agents; Humans; Injections, Intraventricular; Injections, Spinal; Meningitis; Pseudomonas Infections; Tobramycin | 1980 |
Infections and antibiotic prophylaxis in the fulgurated rat bladder.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cefazolin; Electric Injuries; Escherichia coli Infections; Pseudomonas Infections; Rats; Tobramycin; Urinary Bladder; Urinary Bladder Diseases | 1980 |
Pharmacokinetics of tobramycin in cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Biopharmaceutics; Body Surface Area; Body Weight; Child; Child, Preschool; Creatinine; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1982 |
Possible tobramycin delirium.
Topics: Aged; Anti-Bacterial Agents; Delirium; Female; Humans; Pseudomonas Infections; Tobramycin; Urinary Catheterization; Urinary Tract Infections | 1982 |
[Pathogenic flora in hematology patients. Gram-negative germs and their in vitro sensitivity to antibiotics].
Topics: Amikacin; Drug Resistance, Microbial; Gentamicins; Hematologic Diseases; Humans; In Vitro Techniques; Pseudomonas; Pseudomonas Infections; Sisomicin; Tobramycin | 1982 |
[Treatment of Pseudomonas aeruginosa keratitis with tobramycin and gentamicin: animal experiments (author's transl)].
Topics: Animals; Anti-Bacterial Agents; Gentamicins; Keratitis; Pseudomonas Infections; Rabbits; Rats; Tobramycin | 1981 |
[Pseudomonas endocarditis on aortic valve prosthesis. Successful treatment by association of tobramycin-rifampicin-colistin and two reinterventions. Follow-up of 5 years (author's transl)].
Topics: Adult; Aortic Valve; Colistin; Drug Therapy, Combination; Endocarditis, Bacterial; Heart Valve Prosthesis; Humans; Male; Postoperative Complications; Pseudomonas Infections; Rifampin; Tobramycin | 1981 |
[Pseudomonas aeruginosa meningitis in a 4-month-old girl, cured with antibiotic and autovaccine therapy].
Topics: Anti-Bacterial Agents; Female; Humans; Immunotherapy; Infant; Meningitis; Pseudomonas Infections; Tobramycin | 1981 |
[Clinical studies on tobramycin by intravenous drip infusion for Pseudomonas aeruginosa infection in chronic respiratory diseases (author's transl)].
Topics: Adult; Aged; Anti-Bacterial Agents; Chronic Disease; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Pseudomonas Infections; Radiography; Respiratory Tract Infections; Tobramycin | 1981 |
Netilmicin: its in vitro activity and synergism with penicillin compounds.
Topics: Amikacin; Bacteria; Drug Synergism; Enterobacteriaceae Infections; Gentamicins; Humans; Microbial Sensitivity Tests; Netilmicin; Penicillins; Pseudomonas Infections; Sisomicin; Tobramycin | 1980 |
Penicillin-aminoglycoside inactivation: another possible mechanism of interaction.
Topics: Aged; Anti-Bacterial Agents; Biological Assay; Carbenicillin; Drug Interactions; Drug Therapy, Combination; Heparin; Humans; Kidney Failure, Chronic; Male; Pseudomonas Infections; Radioimmunoassay; Tobramycin | 1980 |
Pseudomonas infection of the nose.
Topics: Female; Humans; Middle Aged; Nose Diseases; Pseudomonas Infections; Rhinoplasty; Surgical Wound Infection; Tobramycin | 1980 |
Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Gentamicins; Humans; Lung Diseases; Pseudomonas Infections; Tobramycin | 1980 |
Management of chronic sinusitis in cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Cystic Fibrosis; Endoscopy; Humans; Lung Transplantation; Maxillary Sinus; Nasal Polyps; Nasal Septum; Pneumonia, Bacterial; Preoperative Care; Pseudomonas Infections; Respiratory Tract Infections; Rhinitis; Sinusitis; Sodium Chloride; Therapeutic Irrigation; Tobramycin; Turbinates | 1995 |
Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Eye Infections, Bacterial; Glucocorticoids; Keratitis; Ophthalmic Solutions; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1995 |
Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin.
Topics: Aged; Creatinine; Female; Hearing; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1994 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Denmark; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1994 |
In vitro synergism of ceftriaxone combined with aminoglycosides against Pseudomonas aeruginosa.
Topics: Ceftazidime; Ceftriaxone; Drug Synergism; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1994 |
Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
Topics: Adolescent; Adult; Body Weight; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Humans; Male; Mathematics; Pseudomonas Infections; Regression Analysis; Respiratory Tract Infections; Retrospective Studies; Tobramycin | 1994 |
Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.
Topics: Animals; Drug Carriers; Intubation, Intratracheal; Liposomes; Lung; Male; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Tobramycin | 1994 |
Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.
Topics: Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Pseudomonas Infections; Recurrence; Tobramycin | 1993 |
Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Blood; Colony-Forming Units Assay; Drug Carriers; Liposomes; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Surgical Wound Infection; Tissue Distribution; Tobramycin | 1994 |
Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration.
Topics: Aerosols; Animals; Blood; Female; Guinea Pigs; Lung; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Survival Analysis; Tobramycin | 1993 |
Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Animal; Drug Therapy, Combination; Eye Infections, Bacterial; Keratitis; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin | 1993 |
Acute Pseudomonas infection following total hip replacement.
Topics: Acute Disease; Aged; Ciprofloxacin; Drug Delivery Systems; Hip Prosthesis; Humans; Male; Methylmethacrylates; Postoperative Complications; Pseudomonas Infections; Surgical Wound Infection; Tobramycin | 1993 |
Effectiveness of netilmicin and tobramycin against Pseudomonas aeruginosa in vitro and in an experimental tissue infection in mice.
Topics: Animals; Male; Mice; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1993 |
The effect of electrical currents and tobramycin on Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Colony Count, Microbial; Drug Resistance, Microbial; Electricity; Electronics, Medical; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1995 |
Aminoglycoside toxicity after sternal wound irrigations.
Topics: Anti-Bacterial Agents; Coronary Artery Bypass; Creatinine; Humans; Kanamycin; Male; Middle Aged; Pseudomonas Infections; Surgical Wound Infection; Therapeutic Irrigation; Tobramycin | 1996 |
Topical treatment of Pseudomonas sp-infected corneal ulcers in horses: 70 cases (1977-1994).
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Corneal Ulcer; Female; Gentamicins; Horse Diseases; Horses; Male; Pseudomonas Infections; Retrospective Studies; Tobramycin | 1996 |
Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis.
Topics: Adolescent; Adult; Aerosols; Airway Obstruction; Anti-Bacterial Agents; Bronchodilator Agents; Case-Control Studies; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Prospective Studies; Pseudomonas Infections; Respiratory Mechanics; Statistics, Nonparametric; Tobramycin | 1996 |
Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Time Factors; Tobramycin | 1996 |
Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.
Topics: Animals; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Chronic Disease; Colony Count, Microbial; Liposomes; Lung; Lung Diseases; Mucous Membrane; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Spectrophotometry, Ultraviolet; Tissue Distribution; Tobramycin | 1996 |
Tetany in a child with AIDS receiving intravenous tobramycin.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Bronchiectasis; Child; Drug Monitoring; Female; Humans; Hypocalcemia; Hypokalemia; Kidney Diseases; Magnesium Deficiency; Pseudomonas Infections; Tetany; Tobramycin | 1996 |
Predictive value of several signs of infection as surrogate markers for mortality in a neutropenic guinea pig model of Pseudomonas aeruginosa sepsis.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Ceftazidime; Cephalosporins; Diarrhea; Disease Models, Animal; Female; Guinea Pigs; Imipenem; Meropenem; Movement Disorders; Neutropenia; Predictive Value of Tests; Pseudomonas Infections; Regression Analysis; Respiration; Thienamycins; Time Factors; Tobramycin; Weight Loss | 1997 |
Corneal ulcer associated with contamination of aerosol saline spray tip.
Topics: Aerosols; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Contact Lens Solutions; Contact Lenses, Hydrophilic; Cornea; Corneal Transplantation; Corneal Ulcer; Drug Therapy, Combination; Equipment Contamination; Eye Infections, Bacterial; Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sodium Chloride; Tobramycin | 1997 |
Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
Topics: Alginates; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Depression, Chemical; Dose-Response Relationship, Drug; Gentamicins; Glucuronic Acid; Hexuronic Acids; Humans; Microbial Sensitivity Tests; Netilmicin; Pefloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence | 1996 |
Corneal infection after radial keratotomy.
Topics: Adolescent; Adult; Aspergillosis; Bacteria; Cefazolin; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections; Female; Fungi; Humans; Keratoplasty, Penetrating; Keratotomy, Radial; Male; Natamycin; Ophthalmic Solutions; Pseudomonas Infections; Staphylococcal Infections; Tobramycin; Visual Acuity | 1998 |
Pachymeningitis with multiple cranial neuropathies and unilateral optic neuropathy secondary to Pseudomonas aeruginosa: case report and review.
Topics: Ceftazidime; Cranial Nerve Diseases; Drug Therapy, Combination; Humans; Hypertrophy; Magnetic Resonance Imaging; Male; Meninges; Meningitis, Bacterial; Middle Aged; Optic Nerve Diseases; Paralysis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Tomography, X-Ray Computed | 1998 |
Scleral buckle infection with ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Eye Infections, Bacterial; Humans; Male; Microbial Sensitivity Tests; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Retinal Detachment; Scleral Buckling; Tobramycin | 1998 |
Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azlocillin; Ceftazidime; Cephalosporins; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1999 |
Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
Topics: Acute Disease; Anti-Bacterial Agents; Child, Preschool; Cystic Fibrosis; Female; Humans; Kidney Tubules; Magnesium; Magnesium Deficiency; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1999 |
Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azlocillin; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1999 |
Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Chronic Disease; Disease Models, Animal; Drug Carriers; Liposomes; Lung Diseases; Powders; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Temperature; Tobramycin | 1999 |
Treatment of chronic suppurative otitis media with topical tobramycin and dexamethasone.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Auditory Threshold; Chronic Disease; Cochlea; Dexamethasone; Drug Evaluation; Ear, Middle; Evoked Potentials, Auditory; Glucocorticoids; Macaca fascicularis; Otitis Media, Suppurative; Perilymph; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin | 2000 |
Antibacterial susceptibility patterns of Pseudomonas strains isolated from chronic canine otitis externa.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Chronic Disease; Dog Diseases; Dogs; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Otitis Externa; Pseudomonas; Pseudomonas Infections; Quinolones; Tobramycin | 2000 |
Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Humans; Male; Pneumonia, Bacterial; Predictive Value of Tests; Pseudomonas Infections; Retrospective Studies; Secondary Prevention; Tobramycin; Treatment Outcome | 1999 |
Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit.
Topics: Anti-Bacterial Agents; Bone Marrow Transplantation; Disease Outbreaks; Drug Resistance, Bacterial; Finland; Humans; Intensive Care Units; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2001 |
[The relationship between different serological types of Pseudomonas aeruginosa strain in lower respiratory tract and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchiectasis; Drug Resistance, Microbial; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Serotyping; Tobramycin | 1998 |
Administration of aerosolized antibiotics in cystic fibrosis patients.
Topics: Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Nebulizers and Vaporizers; Opportunistic Infections; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2001 |
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
Topics: Administration, Inhalation; Administration, Oral; Ceftazidime; Child; Child, Preschool; Chronic Disease; Colistin; Colony Count, Microbial; Cystic Fibrosis; DNA, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Female; Genotype; Humans; Imipenem; Infant; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Tobramycin | 2001 |
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Lung Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2001 |
Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Deafness; Humans; Pseudomonas Infections; Tobramycin; United Kingdom | 2002 |
[Inhalational antibiotic therapy in mucoviscidosis. Apropos of a galenic form of tobramycin].
Topics: Administration, Inhalation; Bronchitis; Child; Child, Preschool; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Infant; Infant, Newborn; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2001 |
Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2002 |
Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Colistin; Cystic Fibrosis; Humans; Pseudomonas Infections; Tobramycin | 2002 |
Treatment options for cystic fibrosis: case study and panel discussion.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Macrolides; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2002 |
Hypersensitivity to inhaled TOBI following reaction to gentamicin.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Cystic Fibrosis; Desensitization, Immunologic; Drug Eruptions; Gentamicins; Humans; Male; Pseudomonas Infections; Skin Tests; Tobramycin | 2002 |
Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.
Topics: Amikacin; Aminoglycosides; California; Carbenicillin; Cross Infection; Enterobacteriaceae Infections; Gentamicins; Hospitals, General; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Sisomicin; Tobramycin | 1976 |
Bacteriologic cure of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Amikacin; Animals; Carbenicillin; Drug Evaluation; Guinea Pigs; Keratitis; Male; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1978 |
Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis.
Topics: Absorption; Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Biological Availability; Cornea; Drug Evaluation, Preclinical; Guinea Pigs; Kanamycin; Keratitis; Male; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1978 |
Pseudomonas aeruginosa infection: pathogenesis and therapy.
Topics: Bacterial Vaccines; Burns; Carbenicillin; Cross Infection; Cystic Fibrosis; Gentamicins; Humans; Immunosuppression Therapy; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin; Wound Infection | 1979 |
Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum.
Topics: Aminoglycosides; Blood Bactericidal Activity; Carbenicillin; Drug Synergism; Endocarditis, Bacterial; Gentamicins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1979 |
Pseudomonas aeruginosa keratitis treated with ticarcillin and tobramycin.
Topics: Aged; Anti-Bacterial Agents; Corneal Ulcer; Drug Therapy, Combination; Humans; Keratoconjunctivitis; Male; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1979 |
Pseudomonas aeruginosa keratitis treated with ticarcillin and tobramycin.
Topics: Anti-Bacterial Agents; Corneal Ulcer; Humans; Keratitis; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1979 |
Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Chronic Disease; Colistin; Cystic Fibrosis; Drug Evaluation; Drug Therapy, Combination; Female; Gentamicins; Humans; Infant; Male; Pneumonia; Precipitins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1979 |
Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Colistin; Gentamicins; Mice; Microbial Sensitivity Tests; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1975 |
Antibiotic therapy of experimental Pseudomonas keratitis in guinea pigs.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Carbenicillin; Cornea; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Gentamicins; Guinea Pigs; Humans; Injections, Intramuscular; Keratitis; Kinetics; Male; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1977 |
Progressive necrotizing external otitis: treatment with ticarcillin and tobramycin.
Topics: Anti-Bacterial Agents; Carbenicillin; Cranial Nerves; Drug Therapy, Combination; Ear, External; Gentamicins; Humans; Male; Middle Aged; Necrosis; Otitis Externa; Penicillins; Peripheral Nervous System Diseases; Pseudomonas Infections; Ticarcillin; Tobramycin | 1977 |
[Azlocilline and HR 756 in urosepsis and urinary tract infection with multiresistant pseudomonas and proteus morganii].
Topics: Adolescent; Cephalosporins; Female; Humans; Penicillin Resistance; Penicillins; Proteus Infections; Pseudomonas Infections; Sepsis; Tobramycin; Urinary Tract Infections | 1979 |
Clinical and laboratory study of tobramycin in the treatment of infections due to gram-negative organisms.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Proteus; Proteus Infections; Providencia; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1977 |
Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1977 |
Gentamicin-resistant Pseudomonas aeruginosa: Mayo Clinic Experience, 1970-1976.
Topics: Amikacin; Carbenicillin; Drug Therapy, Combination; Gentamicins; Hospitals, General; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1977 |
Antimicrobial susceptibility of gentamicin-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbenicillin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Sisomicin; Tobramycin | 1977 |
Cross infection in a surgical ward caused by Pseudomonas aeruginosa with transferable resistance to gentamicin and tobramycin.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cross Infection; Drug Resistance, Microbial; Female; Gentamicins; Hospital Departments; Hospital Units; Humans; Ireland; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Surgery Department, Hospital; Tobramycin | 1977 |
Topical tobramycin therapy of experimental Pseudomonas keratitis: an evaluation of some factors that potentially enhance efficacy.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Evaluation Studies as Topic; Guinea Pigs; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1978 |
Corticosteroid in experimentally induced Pseudomonas keratitis: failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Carbenicillin; Guinea Pigs; Injections, Intramuscular; Keratitis; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1978 |
Endocarditis related to transvenous pacemakers. Syndromes and surgical implications.
Topics: Aged; Carbenicillin; Cephalexin; Cephalothin; Endocarditis, Bacterial; Female; Humans; Male; Pacemaker, Artificial; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Staphylococcal Infections; Tobramycin | 1978 |
Cryotherapy for experimental Pseudomonas keratitis.
Topics: Animals; Cryosurgery; Guinea Pigs; Keratitis; Pseudomonas Infections; Rabbits; Tobramycin | 1979 |
Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Radiography; Respiratory Function Tests; Time Factors; Tobramycin | 1979 |
Comparison of therapeutic routes in experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Disease Models, Animal; Guinea Pigs; Humans; Injections; Injections, Intramuscular; Keratitis; Kinetics; Pseudomonas Infections; Rabbits; Tobramycin | 1979 |
Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Infant; Lung Diseases; Pseudomonas Infections; Time Factors; Tobramycin | 1979 |
Experimental Pseudomonas keratitis in guinea-pigs: therapy of moderately severe infections.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Guinea Pigs; Keratitis; Male; Ophthalmic Solutions; Pseudomonas Infections; Tobramycin | 1979 |
Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Administration Schedule; Ear Diseases; Female; Hearing Disorders; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1979 |
[Pseudomonas infections in lungs of children born with cystic fibrosis. Effects and adverse effects during antibiotic therapy with tobramycin and carbenicillin].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Cystic Fibrosis; Drug Evaluation; Female; Humans; Infant; Male; Pneumonia; Prognosis; Pseudomonas Infections; Tobramycin | 1979 |
High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
Topics: Anti-Bacterial Agents; Carbenicillin; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1979 |
Treatment of infections due to Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bronchopneumonia; Burns; Drug Therapy, Combination; Female; Humans; Middle Aged; Neutropenia; Osteochondritis; Pseudomonas Infections; Sepsis; Tobramycin; Urinary Tract Infections | 1977 |
[Studies of tobramycin eye drops. Report 3. Therapeutic effect in experimental Peudomonas keratitis (author's transl)].
Topics: Animals; Anti-Bacterial Agents; Guinea Pigs; Keratitis; Ophthalmic Solutions; Pseudomonas Infections; Tobramycin | 1977 |
Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy.
Topics: Adult; Aminoglycosides; Carbenicillin; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Gentamicins; Humans; Male; Pseudomonas Infections; Tobramycin | 1978 |
Malignant otitis externa.
Topics: Diabetes Complications; Humans; Male; Mastoid; Middle Aged; Otitis Externa; Prognosis; Pseudomonas Infections; Tobramycin | 1978 |
Comparison of 5-episisomicin (Sch 22591), gentamicin, sisomicin, and tobramycin in treatment of experimental Pseudomonas infections in mice.
Topics: Animals; Anti-Bacterial Agents; Drug Evaluation; Gentamicins; Lethal Dose 50; Mice; Pseudomonas Infections; Sisomicin; Stereoisomerism; Tobramycin | 1978 |
Clinical evaluation of tobramycin in urinary tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Resistance, Microbial; Escherichia coli Infections; Humans; Middle Aged; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1976 |
Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa.
Topics: Agglutination Tests; Animals; Humans; Immune Sera; Injections, Intravenous; Male; Mice; Peritoneum; Pseudomonas aeruginosa; Pseudomonas Infections; Serum Globulins; Tobramycin | 1975 |
Therapy of Pseudomonas aeruginosa infections with tobramycin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Female; Gentamicins; Humans; Kinetics; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1975 |
[Bacteriological studies on the therapy of bacillus pyocyaneus infections].
Topics: Ampicillin; Anti-Bacterial Agents; Carbenicillin; Cephalothin; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Gentamicins; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1975 |
In-vitro comparison of four antipseudomonal antibiotics in a general hospital.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Dose-Response Relationship, Drug; Gentamicins; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1976 |
[Action of gentamicin, tobramycin and their combinations with prodigiozan in an experimental infection caused by Pseudomonas aeruginosa].
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gentamicins; Injections, Intramuscular; Injections, Intraperitoneal; Mice; Prodigiosin; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1975 |
Osteolytic lesion indicating Pseudomonas sternal osteomyelitis.
Topics: Accidents, Traffic; Adult; Heroin Dependence; Humans; Male; Middle Aged; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Sternum; Tobramycin | 1976 |
Bacteriological, clinical, and pharmacological investigations with tobramycin in patients with serious urinary tract infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Middle Aged; Nephrectomy; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1976 |
Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1976 |
Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1976 |
Comparative in vitro activity of tobramycin, gentamicin, kanamycin, colistin, carbenicillin, and ticarcillin and clinical isolates of Pseudomonas aeruginosa: epidemiological and therapeutic implications.
Topics: Anti-Bacterial Agents; Carbenicillin; Colistin; Gentamicins; Humans; Kanamycin; Microbial Sensitivity Tests; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1976 |
Tobramycin in the treatment of severe and complicated urinary tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Female; Gentamicins; Humans; Kidney Diseases; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Urinary Tract Infections | 1976 |
Pseudomonas infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Drug Therapy, Combination; Heroin Dependence; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1976 |
Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.
Topics: Anti-Bacterial Agents; Body Fluids; Bronchopneumonia; Empyema; Enterobacteriaceae Infections; Exudates and Transudates; Humans; Male; Pacemaker, Artificial; Peritonitis; Pseudomonas Infections; Staphylococcal Infections; Time Factors; Tobramycin | 1977 |
Pulmonary valve vegetations detected with echocardiography.
Topics: Adult; Autopsy; Echocardiography; Endocarditis, Bacterial; Gentamicins; Humans; Male; Pseudomonas Infections; Pulmonary Valve; Pulmonary Valve Insufficiency; Tobramycin | 1977 |
Successful treatment of Pseudomonas aeruginosa septicaemia and meningitis with neutropenia--the presenting feature of hypogammaglobulinaemia.
Topics: Agammaglobulinemia; Agranulocytosis; Anti-Bacterial Agents; Granulocytes; Immunoglobulin G; Meningitis; Neutropenia; Pseudomonas Infections; Sepsis; Tobramycin | 1977 |
[New aminoglycoside antibiotics].
Topics: Amikacin; Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Kanamycin; Pseudomonas Infections; Tobramycin | 1977 |
Tobramycin in paediatric use.
Topics: Anti-Bacterial Agents; Bacterial Infections; Child; Humans; Injections, Intramuscular; Injections, Intravenous; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1976 |
Treatment of pseudomonas infections in cystic fibrosis using tobramycin.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Pseudomonas Infections; Tobramycin | 1976 |
The use of tombramycin in the management of severe infections. Clinical and pharmacological data.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Creatinine; Enterobacteriaceae Infections; Female; Humans; Klebsiella Infections; Male; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1976 |
Tobramycin and cephalothin sodium in treatment of infected patients with acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Bacterial Infections; Cephalothin; Drug Therapy, Combination; Humans; Klebsiella Infections; Leukemia; Pseudomonas Infections; Tobramycin | 1976 |
Clinical use of tobramycin in patients with surgical infections due to gram-negative bacilli.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Humans; Male; Middle Aged; Pseudomonas Infections; Surgical Wound Infection; Tobramycin | 1976 |
Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Pseudomonas Infections; Sputum; Tobramycin | 1976 |
Emergence of gentamicin-resistant bacteria: experience with tobramycin therapy of infections due to gentamicin-resistant organisms.
Topics: Acinetobacter; Adolescent; Adult; Aged; Alcaligenes; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Female; Gentamicins; Humans; Male; Middle Aged; Pseudomonas; Pseudomonas Infections; Tobramycin | 1976 |
A clinical study on the ototoxic effects of tobramycin.
Topics: Aged; Anti-Bacterial Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas Infections; Tobramycin; Vestibule, Labyrinth | 1976 |
Aminoglycoside therapy of gram-negative bacillary meningitis.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Cerebral Ventricles; Child; Escherichia coli Infections; Gentamicins; Humans; Injections; Injections, Spinal; Klebsiella Infections; Lumbosacral Region; Meningitis; Pseudomonas Infections; Tobramycin | 1975 |
[Drug information. Tobramycin (Nebcina, Eli Lilly)].
Topics: Humans; Pseudomonas Infections; Tobramycin | 1975 |
[Intraocular penetration and effect of tobramycin in experimental Pseudomonas keratitis (author's transl)].
Topics: Animals; Anti-Bacterial Agents; Eye; Keratitis; Pseudomonas Infections; Rabbits; Tobramycin | 1975 |
Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis.
Topics: Animals; Biological Dressings; Collagen; Colony Count, Microbial; Cornea; Corneal Ulcer; Delayed-Action Preparations; Disease Models, Animal; Eye Infections, Bacterial; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1992 |
Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Drug Carriers; Eye Infections, Bacterial; Fibrin; Liposomes; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Random Allocation; Tobramycin | 1992 |
Recurrence of microbial keratitis concomitant with antiinflammatory treatment in an animal model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cornea; Disease Models, Animal; Eye Infections, Bacterial; Keratitis; Methylprednisolone; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Random Allocation; Recurrence; Streptococcus pneumoniae; Tobramycin | 1992 |
Once-daily aminoglycosides.
Topics: Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Gentamicins; Humans; Injections, Intravenous; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1992 |
Efficacy of tobramycin-soaked collagen shields vs tobramycin eyedrop loading dose for sustained treatment of experimental Pseudomonas aeruginosa-induced keratitis in rabbits.
Topics: Administration, Topical; Animals; Biological Dressings; Collagen; Colony Count, Microbial; Cornea; Drug Carriers; Eye Infections, Bacterial; Eyelids; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1992 |
Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Endocarditis, Bacterial; Humans; Imipenem; Male; Pseudomonas Infections; Tobramycin | 1992 |
Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model.
Topics: Administration, Topical; Animals; Aqueous Humor; Chromatography, High Pressure Liquid; Disease Models, Animal; Eye Infections, Bacterial; Keratitis; Ofloxacin; Pseudomonas Infections; Rabbits; Tobramycin | 1992 |
Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Endocarditis, Bacterial; Humans; Imipenem; Male; Pseudomonas Infections; Risk Factors; Tobramycin | 1992 |
Aprotinin treatment of pseudomonal corneal infection.
Topics: Administration, Topical; Animals; Aprotinin; Conjunctiva; Corneal Ulcer; Disease Models, Animal; Drug Administration Routes; Drug Therapy, Combination; Pseudomonas Infections; Rabbits; Tobramycin | 1991 |
Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis.
Topics: Administration, Topical; Animals; Colony Count, Microbial; Conjunctiva; Drug Carriers; Eye Infections, Bacterial; Keratitis; Liposomes; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Random Allocation; Tobramycin | 1991 |
[Otitis externa maligna. Report of a case resistant to ciprofloxacin].
Topics: Aged; Aged, 80 and over; Ceftazidime; Ciprofloxacin; Diabetes Mellitus, Type 1; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1991 |
The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Keratitis; Norfloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1991 |
In vivo inactivation of tobramycin by piperacillin.
Topics: Drug Interactions; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperacillin; Pseudomonas Infections; Tobramycin | 1991 |
[Right endocarditis caused by Pseudomonas aeruginosa in a heroin addict: cure with medical treatment].
Topics: Adult; Ceftazidime; Drug Therapy, Combination; Endocarditis, Bacterial; Heroin Dependence; Humans; Male; Pseudomonas Infections; Tobramycin | 1991 |
Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters.
Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Male; Pneumonia; Pseudomonas Infections; Tobramycin | 1990 |
Acute Pseudomonas chondritis as a sequel to ear piercing.
Topics: Acute Disease; Adult; Cartilage Diseases; Ear Diseases; Ear, External; Female; Humans; Injections, Intravenous; Pseudomonas Infections; Ticarcillin; Tobramycin | 1990 |
Pseudomonas stutzeri synthetic vascular graft infection.
Topics: Aorta, Abdominal; Aortic Aneurysm; Blood Vessel Prosthesis; Female; Femoral Artery; Graft Survival; Humans; Middle Aged; Postoperative Complications; Pseudomonas Infections; Reoperation; Tobramycin; Vancomycin | 1990 |
Septic arthritis caused by treatment resistant Pseudomonas cepacia.
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Infectious; Drug Resistance, Microbial; Female; Humans; Inhalation; Injections, Intra-Articular; Knee Joint; Microbial Sensitivity Tests; Pseudomonas Infections; Tobramycin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 1990 |
Topical anti-inflammatory agents in an animal model of microbial keratitis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Flurbiprofen; Keratitis; Pharmaceutical Vehicles; Pneumococcal Infections; Prednisolone; Pseudomonas Infections; Rabbits; Tobramycin | 1990 |
Topical liposomal delivery of antibiotics in soft tissue infection.
Topics: Administration, Topical; Animals; Colony Count, Microbial; Drug Carriers; Liposomes; Microscopy, Electron; Muscular Diseases; Pseudomonas Infections; Rats; Rats, Inbred Strains; Silver Sulfadiazine; Tobramycin | 1990 |
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumonia; Pneumonia, Pneumococcal; Pseudomonas Infections; Streptococcal Infections; Streptococcus pneumoniae; Superinfection; Tobramycin | 1990 |
Long-term tobramycin aerosol therapy in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Aerosols; Child; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin | 1989 |
Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations.
Topics: ADP Ribose Transferases; Animals; Bacterial Toxins; Ceftazidime; Ciprofloxacin; Dose-Response Relationship, Drug; Exotoxins; Lung; Male; Pancreatic Elastase; Poly(ADP-ribose) Polymerase Inhibitors; Protease Inhibitors; Pseudomonas aeruginosa; Pseudomonas aeruginosa Exotoxin A; Pseudomonas Infections; Rats; Rats, Inbred Strains; Time Factors; Tobramycin; Type C Phospholipases; Virulence Factors | 1989 |
L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Synergism; Female; Gentamicins; Isoindoles; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1989 |
[Experimental study of antibacterial activity, therapeutic effectiveness and toxic properties of the combination of tobramycin and carbenicillin].
Topics: Animals; Carbenicillin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; In Vitro Techniques; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1989 |
Effect of minimal antibiotic treatment on bacterial keratitis.
Topics: Animals; Cell Count; Cornea; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Time Factors; Tobramycin | 1989 |
Pseudomonas corneal ulcer after use of extended-wear rigid gas-permeable contact lens.
Topics: Atropine; Cefazolin; Contact Lenses, Extended-Wear; Corneal Ulcer; Epithelial Cells; Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin; Visual Acuity | 1989 |
[Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
Topics: Animals; Bacterial Vaccines; Burns; Combined Modality Therapy; Female; Immune Sera; Immunization, Passive; Macrophages; Male; Mice; Phagocytosis; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Wound Infection | 1989 |
Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation.
Topics: Culture Media; Drug Resistance, Microbial; Iron; Kinetics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1989 |
Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa.
Topics: Administration, Topical; Animals; Conjugation, Genetic; Cornea; Drug Resistance, Microbial; Eye Infections, Bacterial; Iontophoresis; Keratitis; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Rabbits; Random Allocation; Tobramycin | 1989 |
Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.
Topics: Adolescent; Azlocillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Serotyping; Sputum; Time Factors; Tobramycin | 1989 |
The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis.
Topics: Aerosols; Aged; Humans; Male; Pneumonia; Pseudomonas Infections; Tobramycin | 1989 |
Potential toxicity of tobramycin given daily in a single large dose.
Topics: Child; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Pneumonia; Pseudomonas Infections; Tobramycin | 1989 |
Gentamicin-resistant pseudomonal infection. Rationale for a redefinition of ophthalmic antimicrobial sensitivities.
Topics: Adult; Aged; Cefazolin; Corneal Diseases; Drug Resistance, Microbial; Endophthalmitis; Female; Gentamicins; Humans; Infant, Newborn; Male; Microbial Sensitivity Tests; Pseudomonas Infections; Tobramycin | 1989 |
Ciprofloxacin for Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Meningitis; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Tobramycin | 1986 |
Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aminopeptidases; Azlocillin; CD13 Antigens; Child; Child, Preschool; Creatinine; Cystic Fibrosis; Female; Hexosaminidases; Humans; Kidney; Male; Proteinuria; Pseudomonas Infections; Tobramycin | 1986 |
The use of a radiorespirometric assay for testing the antibiotic sensitivity of catheter-associated bacteria.
Topics: Carbon Dioxide; Carbon Radioisotopes; Cross Infection; Dose-Response Relationship, Drug; Equipment Contamination; Glutamates; Glutamic Acid; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin; Urinary Catheterization; Urinary Tract Infections | 1987 |
Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
Topics: Animals; Azlocillin; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Tobramycin | 1985 |
Intracanalicular collagen implants enhance topical antibiotic bioavailability.
Topics: Administration, Topical; Animals; Biological Availability; Collagen; Colony Count, Microbial; Cornea; Disease Models, Animal; Eye Infections, Bacterial; Keratitis; Lacrimal Duct Obstruction; Prostheses and Implants; Pseudomonas Infections; Rabbits; Tears; Tobramycin | 1986 |
Diversity of determinants encoding carbenicillin, gentamicin, and tobramycin resistance in nosocomial Pseudomonas aeruginosa.
Topics: Carbenicillin; Chromosomes, Bacterial; Conjugation, Genetic; Cross Infection; DNA Transposable Elements; DNA, Bacterial; Gentamicins; Humans; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Sequence Homology, Nucleic Acid; Serratia marcescens; Tobramycin | 1986 |
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Cystic Fibrosis; Denmark; Disease Outbreaks; Drug Resistance, Microbial; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Patient Isolation; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1986 |
Challenging conventional aminoglycoside dosing regimens. The value of experimental models.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Drug Administration Schedule; Guinea Pigs; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin | 1986 |
[Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
Topics: Animals; Bacterial Vaccines; Burns; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunization, Passive; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1986 |
[Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization].
Topics: Animals; Bacterial Vaccines; Burns; Combined Modality Therapy; Drug Evaluation, Preclinical; Immunization; Immunization, Passive; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1986 |
[Treatment of an infection due to the intraperitoneal inoculation of mice with Pseudomonas aeruginosa with tobramycin and hyperimmune Pseudomonas aeruginosa plasma used per se and in combination].
Topics: Animals; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunization, Passive; Injections, Intraperitoneal; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1986 |
Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Adolescent; Adult; beta-Lactamases; Ceftriaxone; Child; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1986 |
Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 1986 |
Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.
Topics: Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Meningitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1986 |
Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
Topics: Animals; Azlocillin; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Female; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Tobramycin | 1987 |
Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bronchopneumonia; Child; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Cystic Fibrosis; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipenem; Kinetics; Male; Microbial Sensitivity Tests; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Thienamycins; Tobramycin | 1987 |
Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host.
Topics: Agranulocytosis; Animals; Antibodies, Monoclonal; Drug Therapy, Combination; Guinea Pigs; Immunization, Passive; Lung; Macrophages; Neutropenia; Neutrophils; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Ticarcillin; Tobramycin | 1987 |
Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients.
Topics: Adult; Aged; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cefsulodin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1987 |
Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.
Topics: Animals; Ceftazidime; Drug Synergism; Drug Therapy, Combination; Female; Guinea Pigs; Male; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1987 |
Susceptibility of 100 blood isolates of Pseudomonas aeruginosa to 19 antipseudomonal antibiotics: old and new.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tobramycin | 1987 |
Therapeutic strategies for Pseudomonas aeruginosa pneumonia in the myelosuppressed host.
Topics: Agranulocytosis; Animals; Anti-Bacterial Agents; Combined Modality Therapy; Guinea Pigs; Immunoglobulin G; Immunoglobulins, Intravenous; Neutropenia; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1987 |
In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
Topics: Aztreonam; Cystic Fibrosis; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Gentamicins; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1987 |
Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.
Topics: beta-Lactamases; Ceftazidime; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1987 |
Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit.
Topics: Animals; Cornea; Injections; Iontophoresis; Keratitis; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1988 |
The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice.
Topics: Agranulocytosis; Animals; Ciprofloxacin; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1987 |
The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice.
Topics: Agranulocytosis; Animals; Ciprofloxacin; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1988 |
Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients.
Topics: Adolescent; Adult; Ceftazidime; Child; Cost-Benefit Analysis; Cystic Fibrosis; Home Care Services; Hospitalization; Humans; Infusions, Intravenous; Penicillins; Pseudomonas Infections; Ticarcillin; Tobramycin | 1988 |
[Pseudomonas aeruginosa and surgical intensive care units].
Topics: Cross Infection; Drug Resistance, Microbial; Enterobacter; Humans; Intensive Care Units; Klebsiella pneumoniae; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Surgical Procedures, Operative; Tobramycin | 1988 |
The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.
Topics: Abscess; Animals; DNA Replication; Drug Administration Schedule; Hair Cells, Auditory; Inflammation; Inulin; Kidney; Kidney Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred F344; Tobramycin | 1988 |
Use of collagen corneal shields in the treatment of bacterial keratitis.
Topics: Animals; Aqueous Humor; Bandages; Collagen; Colony-Forming Units Assay; Eye; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1988 |
Mechanisms of aminoglycoside resistance in variants of Pseudomonas aeruginosa isolated during treatment of experimental endocarditis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport, Active; Cell Membrane; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Endocarditis, Bacterial; Kinetics; Membrane Potentials; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1988 |
Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas.
Topics: Animals; Iontophoresis; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1988 |
Treatment of experimental Pseudomonas keratitis using collagen shields containing tobramycin.
Topics: Administration, Topical; Animals; Collagen; Contact Lenses; Delayed-Action Preparations; Evaluation Studies as Topic; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 1988 |
Frontal sinus mucopyocele in cystic fibrosis.
Topics: Adolescent; Adult; Cystic Fibrosis; Diplopia; Exophthalmos; Female; Frontal Sinus; Humans; Male; Mucocele; Paranasal Sinus Diseases; Pseudomonas Infections; Suppuration; Tobramycin; Tomography, X-Ray Computed | 1988 |
Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bone and Bones; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Tobramycin | 1985 |
Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Aerosols; Child; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin | 1988 |
Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; Drug Therapy, Combination; Eye Diseases; Female; Ketorolac Tromethamine; Pseudomonas Infections; Pyrroles; Rabbits; Tobramycin; Tolmetin; Tromethamine | 1988 |
Ceftriaxone-associated cholecystitis.
Topics: Acute Disease; Adolescent; Arthritis, Infectious; Ceftriaxone; Cholecystitis; Female; Humans; Osteochondritis; Pseudomonas Infections; Tobramycin; Ultrasonography | 1988 |
Successful therapy of Pseudomonas aeruginosa endocarditis with ceftazidime and tobramycin.
Topics: Adult; Ceftazidime; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Opioid-Related Disorders; Pseudomonas Infections; Tobramycin | 1987 |
In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.
Topics: Amiloride; Child; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections; Tobramycin | 1988 |
Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.
Topics: Animals; Drug Therapy, Combination; Guinea Pigs; Mezlocillin; Neutropenia; Pneumonia; Pseudomonas Infections; Tobramycin | 1988 |
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
Topics: Adolescent; Anti-Bacterial Agents; Cystic Fibrosis; Denmark; Female; Follow-Up Studies; Humans; Lactams; Lung Diseases; Male; Pseudomonas Infections; Respiratory Function Tests; Tobramycin | 1987 |
Pseudomonas osteomyelitis of the spine. Report of a case not associated with drug abuse.
Topics: Aged; Humans; Male; Osteomyelitis; Pseudomonas Infections; Radiography; Spondylitis; Thoracic Vertebrae; Ticarcillin; Tobramycin | 1987 |
Corneal ulcers related to contact lens use.
Topics: Cefazolin; Contact Lenses; Contact Lenses, Extended-Wear; Corneal Ulcer; Humans; Pseudomonas Infections; Tobramycin; Uveitis, Anterior | 1986 |
Failure of therapy in pseudomonas endocarditis: selection of resistant mutants.
Topics: Adult; beta-Lactamases; Electrophoresis, Agar Gel; Endocarditis, Bacterial; Female; Humans; Isoelectric Focusing; Male; Microbial Sensitivity Tests; Mutation; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Tobramycin | 1986 |
Postoperative Pseudomonas urinary tract infections as a source of bacterial contamination of an autogenous vein graft.
Topics: Aged; Blood Vessel Prosthesis; Drug Therapy, Combination; Female; Humans; Middle Aged; Pseudomonas Infections; Saphenous Vein; Surgical Wound Infection; Ticarcillin; Tobramycin; Transplantation, Autologous; Urinary Tract Infections | 1987 |
Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients.
Topics: Adolescent; Adult; Cystic Fibrosis; Female; Humans; Kinetics; Male; Pseudomonas Infections; Tobramycin | 1987 |
Comparative bioavailability and efficacy of fortified topical tobramycin.
Topics: Animals; Bacterial Infections; Biological Availability; Disease Models, Animal; Eye Diseases; Keratitis; Kinetics; Male; Ophthalmic Solutions; Pseudomonas Infections; Rabbits; Rats; Rats, Inbred Strains; Tears; Tobramycin | 1987 |
Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
Topics: Adolescent; Adult; Child; Cystic Fibrosis; Female; Hearing Loss, Sensorineural; Humans; Kidney Diseases; Labyrinth Diseases; Male; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1987 |
Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Topics: Acute Disease; Adolescent; Adult; Child; Chronic Disease; Cystic Fibrosis; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1987 |
Novel approaches for the use of aminoglycosides: the value of experimental models.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacterial Infections; Disease Models, Animal; Endocarditis, Bacterial; Guinea Pigs; Humans; Pneumonia; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin | 1986 |
Cefsulodin in treatment of Pseudomonas urinary tract infection in patients with spinal cord injury. Comparison with aminoglycosides.
Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cefsulodin; Humans; Male; Middle Aged; Pseudomonas Infections; Spinal Cord Injuries; Time Factors; Tobramycin; Urinary Tract Infections | 1986 |
Invasive external otitis: review of 12 cases.
Topics: Adult; Aged; Diabetes Complications; Female; Hearing Aids; Humans; Male; Middle Aged; Otitis Externa; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Swimming; Tobramycin | 1985 |
In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis.
Topics: Anti-Bacterial Agents; Aztreonam; Cefsulodin; Drug Synergism; Endocarditis, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Ticarcillin; Tobramycin | 1985 |
[Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
Topics: Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Vaccines; Chronic Disease; Combined Modality Therapy; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Mice; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tobramycin | 1985 |
Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis.
Topics: Adult; Endocarditis, Bacterial; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Pseudomonas Infections; Tobramycin | 1986 |
Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
Topics: Adolescent; Adult; Age Factors; Body Weight; Child; Chronic Disease; Cystic Fibrosis; Female; Half-Life; Humans; Kinetics; Male; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin | 1985 |
Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
Topics: Adolescent; Adult; Carbenicillin; Child; Cystic Fibrosis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Pseudomonas Infections; Sputum; Tobramycin; Vital Capacity | 1985 |